wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
:	O
no	O
strict	O
genotype	O
-	O
phenotype	O
correlations	O
but	O
clustering	O
of	O
missense	O
mutations	O
in	O
the	O
amino	O
-	O
terminal	O
part	O
of	O
the	O
wasp	O
gene	O
product	O
.	O
	
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
protein	O
(	O
wasp	O
)	O
gene	O
was	O
found	O
to	O
be	O
mutated	O
in	O
patients	O
presenting	O
with	O
was	B-Disease
and	O
in	O
patients	O
showing	O
x	B-Disease
-	I-Disease
linked	I-Disease
thrombocytopenia	I-Disease
.	O
	
no	O
genotype	O
-	O
phenotype	O
correlation	O
emerged	O
after	O
a	O
comparison	O
of	O
the	O
identified	O
mutations	O
with	O
the	O
resulting	O
clinical	O
picture	O
for	O
a	O
classical	O
was	B-Disease
phenotype	O
.	O
	
influence	O
of	O
pax6	O
gene	O
dosage	O
on	O
development	O
:	O
overexpression	O
causes	O
severe	O
eye	B-Disease
abnormalities	I-Disease
.	O
	
aniridia	B-Disease
in	O
man	O
and	O
small	O
eye	O
in	O
mice	O
are	O
semidominant	B-Disease
developmental	I-Disease
disorders	I-Disease
caused	O
by	O
mutations	O
within	O
the	O
paired	O
box	O
gene	O
pax6	O
.	O
	
whereas	O
heterozygotes	O
suffer	O
from	O
iris	B-Disease
hypoplasia	I-Disease
,	O
homozygous	O
mice	O
lack	O
eyes	O
and	O
nasal	O
cavities	O
and	O
exhibit	O
brain	B-Disease
abnormalities	I-Disease
.	O
	
strikingly	O
,	O
mice	O
carrying	O
multiple	O
copies	O
on	O
a	O
wild	O
-	O
type	O
background	O
show	O
specific	O
developmental	B-Disease
abnormalities	I-Disease
of	I-Disease
the	I-Disease
eye	I-Disease
,	O
but	O
not	O
of	O
other	O
tissues	O
expressing	O
the	O
gene	O
.	O
	
we	O
provide	O
evidence	O
that	O
not	O
only	O
reduced	O
,	O
but	O
also	O
increased	O
levels	O
of	O
transcriptional	O
regulators	O
can	O
cause	O
developmental	B-Disease
defects	I-Disease
.	O
	
.	O
	
this	O
question	O
is	O
of	O
particular	O
interest	O
for	O
the	O
human	O
enzyme	O
galactose	O
-	O
l	O
-	O
phosphate	O
uridylyl	O
-	O
transferase	O
(	O
galt	O
)	O
,	O
impairment	O
of	O
which	O
results	O
in	O
the	O
inherited	B-Disease
metabolic	I-Disease
disorder	I-Disease
galactosemia	B-Disease
,	O
because	O
many	O
if	O
not	O
most	O
patients	O
studied	O
to	O
date	O
are	O
compound	O
heterozygotes	O
rather	O
than	O
TRUE	O
molecular	O
homozygotes	O
.	O
	
these	O
results	O
are	O
significant	O
not	O
only	O
in	O
terms	O
of	O
their	O
implications	O
for	O
furthering	O
our	O
understanding	O
of	O
galactosemia	B-Disease
and	O
galt	O
holoenzyme	O
structure	O
-	O
function	O
relationships	O
but	O
also	O
because	O
the	O
system	O
described	O
may	O
serve	O
as	O
a	O
model	O
for	O
similar	O
studies	O
of	O
other	O
complexes	O
composed	O
of	O
multiple	O
subunits	O
.	O
	
.	O
	
apoptosis	O
has	O
recently	O
been	O
recognized	O
as	O
a	O
mode	O
of	O
cell	O
death	O
in	O
huntington	B-Disease
disease	I-Disease
(	O
hd	B-Disease
)	O
.	O
	
here	O
we	O
show	O
that	O
apoptotic	O
extracts	O
and	O
apopain	O
itself	O
specifically	O
cleave	O
the	O
hd	B-Disease
gene	O
product	O
,	O
huntingtin	O
.	O
	
our	O
results	O
show	O
that	O
huntingtin	O
is	O
cleaved	O
by	O
cysteine	O
proteases	O
and	O
suggest	O
that	O
hd	B-Disease
might	O
be	O
a	O
disorder	B-Disease
of	I-Disease
inappropriate	I-Disease
apoptosis	I-Disease
.	O
	
.	O
	
to	O
begin	O
to	O
address	O
the	O
hypothesis	O
that	O
abnormal	O
regulation	O
of	O
the	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
susceptibility	O
gene	O
brca1	O
is	O
a	O
critical	O
step	O
in	O
sporadic	O
breast	O
/	O
ovarian	O
tumorigenesis	O
,	O
we	O
have	O
determined	O
the	O
detailed	O
structure	O
of	O
the	O
brca1	O
genomic	O
region	O
.	O
	
deletion	O
of	O
small	O
nuclear	O
ribonucleoprotein	O
polypeptide	O
n	O
(	O
snrpn	O
)	O
in	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
:	O
two	O
sibs	O
with	O
the	O
typical	O
phenotype	O
without	O
a	O
cytogenetic	O
deletion	O
in	O
chromosome	O
15q	O
.	O
	
the	O
small	O
nuclear	O
ribonucleoprotein	O
polypeptide	O
n	O
(	O
snrpn	O
)	O
gene	O
is	O
regarded	O
as	O
one	O
of	O
the	O
candidates	O
for	O
prader	B-Disease
-	I-Disease
willi	I-Disease
syndrome	I-Disease
(	O
pws	B-Disease
)	O
.	O
	
we	O
describe	O
two	O
sibs	O
with	O
typical	O
pws	B-Disease
presenting	O
deletion	O
of	O
snrpn	O
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
fish	O
)	O
.	O
	
this	O
implies	O
a	O
smaller	O
deletion	O
limited	O
to	O
the	O
pws	B-Disease
critical	O
region	O
.	O
	
fish	O
with	O
a	O
snrpn	O
probe	O
will	O
permit	O
analysis	O
of	O
pws	B-Disease
patients	O
with	O
limited	O
deletions	O
not	O
detectable	O
with	O
other	O
probes	O
.	O
	
.	O
	
expression	O
of	O
the	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
disease	I-Disease
tumour	I-Disease
suppressor	O
gene	O
during	O
human	O
embryogenesis	O
.	O
	
the	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
(	I-Disease
vhl	I-Disease
)	I-Disease
disease	I-Disease
product	O
is	O
thought	O
to	O
down	O
-	O
regulate	O
transcription	O
by	O
antagonizing	O
elongin	O
-	O
enhanced	O
transcriptional	O
elongation	O
.	O
	
germline	O
vhl	B-Disease
gene	O
mutations	O
predispose	O
to	O
the	O
development	O
of	O
retinal	B-Disease
,	I-Disease
cerebellar	I-Disease
and	I-Disease
spinal	I-Disease
haemangioblastomas	I-Disease
,	O
renal	B-Disease
cell	I-Disease
carcinoma	I-Disease
and	O
phaeochromocytoma	B-Disease
.	O
	
in	O
addition	O
,	O
somatic	O
inactivation	O
of	O
the	O
vhl	B-Disease
gene	O
is	O
frequent	O
in	O
sporadic	B-Disease
renal	I-Disease
cell	I-Disease
carcinoma	I-Disease
and	O
haemangioblastoma	B-Disease
.	O
	
regulation	O
of	O
transcript	O
elongation	O
is	O
an	O
important	O
control	O
mechanism	O
for	O
gene	O
expression	O
and	O
the	O
vhl	B-Disease
gene	O
might	O
modify	O
the	O
expression	O
of	O
proto	O
-	O
oncogenes	O
and	O
growth	O
suppressor	O
genes	O
during	O
embryogenesis	O
.	O
	
we	O
therefore	O
investigated	O
the	O
expression	O
of	O
vhl	B-Disease
mrna	O
during	O
human	O
embryogenesis	O
by	O
in	O
situ	O
hybridization	O
studies	O
at	O
4	O
,	O
6	O
and	O
10	O
weeks	O
post	O
conception	O
.	O
	
although	O
vhl	B-Disease
mrna	O
was	O
expressed	O
in	O
all	O
three	O
germ	O
layers	O
,	O
strong	O
expression	O
was	O
noted	O
in	O
the	O
central	O
nervous	O
system	O
,	O
kidneys	O
,	O
testis	O
and	O
lung	O
.	O
	
within	O
the	O
kidney	O
,	O
vhl	B-Disease
mrna	O
was	O
differentially	O
expressed	O
within	O
renal	O
tubules	O
suggesting	O
that	O
the	O
vhl	B-Disease
gene	O
product	O
may	O
have	O
a	O
specific	O
role	O
in	O
kidney	O
development	O
.	O
	
two	O
alternatively	O
spliced	O
vhl	B-Disease
mrnas	O
characterized	O
by	O
inclusion	O
(	O
isoform	O
i	O
)	O
or	O
exclusion	O
(	O
isoform	O
ii	O
)	O
of	O
exon	O
2	O
are	O
transcribed	O
in	O
adult	O
tissues	O
.	O
	
to	O
investigate	O
if	O
the	O
two	O
isoforms	O
are	O
differentially	O
expressed	O
during	O
embryogenesis	O
,	O
vhl	B-Disease
mrna	O
was	O
reverse	O
transcribed	O
from	O
13	O
fetal	O
tissues	O
(	O
8	O
-	O
10	O
weeks	O
gestation	O
)	O
.	O
	
the	O
quantitative	O
distribution	O
of	O
vhl	B-Disease
mrna	O
within	O
fetal	O
tissues	O
reflected	O
that	O
seen	O
by	O
in	O
situ	O
hybridization	O
and	O
the	O
ratio	O
of	O
the	O
two	O
vhl	B-Disease
isoforms	O
was	O
similar	O
between	O
tissues	O
.	O
	
although	O
the	O
genes	O
regulated	O
by	O
the	O
vhl	B-Disease
gene	O
product	O
have	O
not	O
yet	O
been	O
identified	O
,	O
our	O
findings	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
vhl	B-Disease
-	O
mediated	O
control	O
of	O
transcriptional	O
elongation	O
may	O
have	O
a	O
role	O
in	O
normal	O
human	O
development	O
.	O
	
.	O
	
genetic	O
heterogeneity	O
in	O
hereditary	B-Disease
breast	I-Disease
cancer	I-Disease
:	O
role	O
of	O
brca1	O
and	O
brca2	O
.	O
	
the	O
common	O
hereditary	O
forms	O
of	O
breast	B-Disease
cancer	I-Disease
have	O
been	O
largely	O
attributed	O
to	O
the	O
inheritance	O
of	O
mutations	O
in	O
the	O
brca1	O
or	O
brca2	O
genes	O
.	O
	
however	O
,	O
it	O
is	O
not	O
yet	O
clear	O
what	O
proportion	O
of	O
hereditary	B-Disease
breast	I-Disease
cancer	I-Disease
is	O
explained	O
by	O
brca1	O
and	O
brca2	O
or	O
by	O
some	O
other	O
unidentified	O
susceptibility	O
gene	O
(	O
s	O
)	O
.	O
	
we	O
describe	O
the	O
proportion	O
of	O
hereditary	B-Disease
breast	I-Disease
cancer	I-Disease
explained	O
by	O
brca1	O
or	O
brca2	O
in	O
a	O
sample	O
of	O
north	O
american	O
hereditary	B-Disease
breast	I-Disease
cancers	I-Disease
and	O
assess	O
the	O
evidence	O
for	O
additional	O
susceptibility	O
genes	O
that	O
may	O
confer	O
hereditary	B-Disease
breast	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
risk	O
.	O
	
twenty	O
-	O
three	O
families	O
were	O
identified	O
through	O
two	O
high	O
-	O
risk	O
breast	B-Disease
cancer	I-Disease
research	O
programs	O
.	O
	
genetic	O
analysis	O
was	O
undertaken	O
to	O
establish	O
linkage	O
between	O
the	O
breast	B-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
cases	O
and	O
markers	O
on	O
chromosomes	O
17q	O
(	O
brca1	O
)	O
and	O
13q	O
(	O
brca2	O
)	O
.	O
	
the	O
pattern	O
of	O
hereditary	B-Disease
cancer	I-Disease
in	O
14	O
(	O
61	O
%	O
)	O
of	O
the	O
23	O
families	O
studied	O
was	O
attributed	O
to	O
brca1	O
by	O
a	O
combination	O
of	O
linkage	O
and	O
mutation	O
analyses	O
.	O
	
brca1	O
and	O
brca2	O
probably	O
explain	O
the	O
majority	O
of	O
hereditary	B-Disease
breast	I-Disease
cancer	I-Disease
that	O
exists	O
in	O
the	O
north	O
american	O
population	O
.	O
	
however	O
,	O
one	O
or	O
more	O
additional	O
genes	O
may	O
yet	O
be	O
found	O
that	O
explain	O
some	O
proportion	O
of	O
hereditary	B-Disease
breast	I-Disease
cancer	I-Disease
.	O
	
.	O
	
an	O
intronic	O
mutation	O
in	O
a	O
lariat	O
branchpoint	O
sequence	O
is	O
a	O
direct	O
cause	O
of	O
an	O
inherited	B-Disease
human	I-Disease
disorder	I-Disease
(	O
fish	B-Disease
-	I-Disease
eye	I-Disease
disease	I-Disease
)	O
.	O
	
three	O
sisters	O
were	O
shown	O
to	O
suffer	O
from	O
fish	B-Disease
-	I-Disease
eye	I-Disease
disease	I-Disease
(	O
fed	B-Disease
)	O
,	O
a	O
disorder	O
which	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
coding	O
for	O
lecithin	O
cholesterol	O
acyltransferase	O
(	O
lcat	O
)	O
.	O
	
sequencing	O
of	O
the	O
lcat	O
gene	O
of	O
all	O
three	O
probands	O
revealed	O
compound	O
heterozygosity	O
for	O
a	O
missense	O
mutation	O
in	O
exon	O
4	O
which	O
is	O
reported	O
to	O
underlie	O
the	O
fed	B-Disease
phenotype	O
,	O
and	O
a	O
point	O
mutation	O
located	O
in	O
intron	O
4	O
(	O
ivs4	O
t	O
-	O
22c	O
)	O
.	O
	
in	O
conclusion	O
,	O
we	O
demonstrated	O
that	O
a	O
point	O
mutation	O
in	O
a	O
lariat	O
branchpoint	O
consensus	O
sequence	O
causes	O
a	O
nan	O
allele	O
in	O
a	O
patient	O
with	O
fed	B-Disease
.	O
	
mutations	O
associated	O
with	O
variant	O
phenotypes	O
in	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
.	O
	
we	O
have	O
identified	O
14	O
families	O
with	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
a	B-Disease
-	I-Disease
t	I-Disease
)	O
in	O
which	O
mutation	O
of	O
the	O
atm	O
gene	O
is	O
associated	O
with	O
a	O
less	O
severe	O
clinical	O
and	O
cellular	O
phenotype	O
(	O
approximately	O
10	O
%	O
-	O
15	O
%	O
of	O
a	B-Disease
-	I-Disease
t	I-Disease
families	O
identified	O
in	O
the	O
united	O
kingdom	O
)	O
.	O
	
the	O
second	O
a	B-Disease
-	I-Disease
t	I-Disease
allele	O
has	O
a	O
different	O
mutation	O
in	O
each	O
patient	O
.	O
	
the	O
level	O
of	O
the	O
137	O
-	O
bp	O
pcr	O
product	O
containing	O
the	O
insertion	O
was	O
lowest	O
in	O
two	O
patients	O
who	O
showed	O
a	O
later	O
onset	O
of	O
cerebellar	B-Disease
ataxia	I-Disease
.	O
	
mutations	O
detected	O
in	O
two	O
of	O
four	O
of	O
these	O
are	O
missense	O
mutations	O
,	O
normally	O
rare	O
in	O
a	B-Disease
-	I-Disease
t	I-Disease
patients	O
.	O
	
the	O
demonstration	O
of	O
mutations	O
giving	O
rise	O
to	O
a	O
slightly	O
milder	O
phenotype	O
in	O
a	B-Disease
-	I-Disease
t	I-Disease
raises	O
the	O
interesting	O
question	O
of	O
what	O
range	O
of	O
phenotypes	O
might	O
occur	O
in	O
individuals	O
in	O
whom	O
both	O
mutations	O
are	O
milder	O
.	O
	
mutation	O
of	O
the	O
vhl	O
gene	O
is	O
associated	O
exclusively	O
with	O
the	O
development	O
of	O
non	B-Disease
-	I-Disease
papillary	I-Disease
renal	I-Disease
cell	I-Disease
carcinomas	I-Disease
.	O
	
to	O
define	O
the	O
possible	O
role	O
of	O
the	O
vhl	B-Disease
gene	O
in	O
the	O
development	O
of	O
sporadic	B-Disease
renal	I-Disease
cell	I-Disease
carcinomas	I-Disease
,	O
91	O
different	O
parenchymal	B-Disease
tumours	I-Disease
of	I-Disease
the	I-Disease
kidney	I-Disease
have	O
been	O
investigated	O
for	O
mutation	O
of	O
the	O
vhl	B-Disease
gene	O
by	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
sscp	O
)	O
and	O
/	O
or	O
heteroduplex	O
(	O
hd	O
)	O
techniques	O
.	O
	
chromosome	O
3p	O
deletion	O
was	O
detected	O
in	O
98	O
per	O
cent	O
of	O
non	B-Disease
-	I-Disease
papillary	I-Disease
renal	I-Disease
cell	I-Disease
carcinomas	I-Disease
and	O
in	O
25	O
per	O
cent	O
of	O
chromophobe	O
renal	B-Disease
cell	I-Disease
carcinomas	I-Disease
.	O
	
in	O
22	O
of	O
the	O
43	O
non	B-Disease
-	I-Disease
papillary	I-Disease
renal	I-Disease
cell	I-Disease
carcinomas	I-Disease
,	O
abnormally	O
migrating	O
dna	O
bands	O
were	O
detected	O
by	O
sscp	O
and	O
/	O
or	O
hd	O
analysis	O
.	O
	
no	O
mobility	O
shift	O
was	O
seen	O
in	O
any	O
of	O
the	O
23	O
chromophobe	O
renal	B-Disease
cell	I-Disease
carcinomas	I-Disease
.	O
	
in	O
addition	O
,	O
15	O
papillary	B-Disease
renal	I-Disease
cell	I-Disease
tumours	I-Disease
and	O
ten	O
renal	B-Disease
oncocytomas	I-Disease
,	O
which	O
are	O
characterized	O
by	O
genetic	O
changes	O
other	O
than	O
loss	O
of	O
chromosome	O
3p	O
sequences	O
,	O
were	O
analysed	O
for	O
mutation	O
of	O
the	O
vhl	B-Disease
gene	O
.	O
	
none	O
of	O
these	O
tumours	B-Disease
showed	O
abnormal	O
migration	O
patterns	O
.	O
	
the	O
results	O
indicate	O
that	O
mutation	O
of	O
the	O
vhl	B-Disease
gene	O
is	O
associated	O
exclusively	O
with	O
the	O
development	O
of	O
non	B-Disease
-	I-Disease
papillary	I-Disease
renal	I-Disease
cell	I-Disease
carcinoma	I-Disease
.	O
	
.	O
	
the	O
emery	B-Disease
-	I-Disease
dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
protein	O
,	O
emerin	O
,	O
is	O
a	O
nuclear	O
membrane	O
protein	O
.	O
	
a	O
muscle	O
biopsy	O
from	O
an	O
emery	B-Disease
-	I-Disease
dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
emdm	B-Disease
)	O
patient	O
showed	O
complete	O
absence	O
of	O
emerin	O
by	O
both	O
western	O
blotting	O
and	O
immunohistochemistry	O
,	O
suggesting	O
a	O
simple	O
diagnostic	O
antibody	O
test	O
for	O
edmd	B-Disease
families	O
.	O
	
mutation	O
of	O
msh3	O
in	O
endometrial	B-Disease
cancer	I-Disease
and	O
evidence	O
for	O
its	O
functional	O
role	O
in	O
heteroduplex	O
repair	O
.	O
	
many	O
human	O
tumours	B-Disease
have	O
length	O
alterations	O
in	O
repetitive	O
sequence	O
elements	O
.	O
	
although	O
this	O
microsatellite	B-Disease
instability	I-Disease
has	O
been	O
attributed	O
to	O
mutations	O
in	O
four	O
dna	O
mismatch	O
repair	O
genes	O
in	O
hereditary	B-Disease
nonpolyposis	I-Disease
colorectal	I-Disease
cancer	I-Disease
(	O
hnpcc	B-Disease
)	O
kindreds	O
,	O
many	O
sporadic	B-Disease
tumours	I-Disease
exhibit	O
instability	O
but	O
no	O
detectable	O
mutations	O
in	O
these	O
genes	O
.	O
	
thus	O
,	O
we	O
screened	O
16	O
endometrial	B-Disease
carcinomas	I-Disease
with	O
microsatellite	O
instability	O
for	O
alterations	O
in	O
fen1	O
(	O
the	O
human	O
homolog	O
of	O
rth	O
)	O
and	O
in	O
msh3	O
(	O
refs	O
12	O
-	O
14	O
)	O
.	O
	
although	O
we	O
found	O
no	O
fen1	O
mutations	O
,	O
a	O
frameshift	O
mutation	O
in	O
msh3	O
was	O
observed	O
in	O
an	O
endometrial	B-Disease
carcinoma	I-Disease
and	O
in	O
an	O
endometrial	B-Disease
carcinoma	I-Disease
cell	O
line	O
.	O
	
together	O
the	O
data	O
suggest	O
that	O
the	O
msh3	O
gene	O
encodes	O
a	O
product	O
that	O
functions	O
in	O
repair	O
of	O
some	O
but	O
not	O
all	O
pre	O
-	O
mutational	O
intermediates	O
,	O
its	O
mutation	O
in	O
tumours	B-Disease
can	O
result	O
in	O
genomic	O
instability	O
and	O
,	O
as	O
in	O
yeast	O
,	O
msh3	O
and	O
msh6	O
are	O
partially	O
redundant	O
for	O
mismatch	O
repair	O
.	O
	
.	O
	
comparative	O
genome	O
mapping	O
of	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
region	O
in	O
mouse	O
,	O
rat	O
,	O
and	O
syrian	O
hamster	O
.	O
	
chromosomal	O
locations	O
of	O
the	O
atm	O
(	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
at	B-Disease
)	O
-	O
mutated	O
)	O
and	O
acat1	O
(	O
mitochondrial	O
acetoacetyl	O
-	O
coa	O
thiolase	O
)	O
genes	O
in	O
mouse	O
,	O
rat	O
,	O
and	O
syrian	O
hamster	O
were	O
determined	O
by	O
direct	O
r	O
-	O
banding	O
fish	O
.	O
	
fine	O
genetic	O
linkage	O
mapping	O
of	O
the	O
mouse	O
at	B-Disease
region	O
was	O
performed	O
using	O
the	O
interspecific	O
backcross	O
mice	O
.	O
	
an	O
animal	O
model	O
for	O
norrie	B-Disease
disease	I-Disease
(	O
nd	B-Disease
)	O
:	O
gene	O
targeting	O
of	O
the	O
mouse	O
nd	B-Disease
gene	O
.	O
	
in	O
order	O
to	O
elucidate	O
the	O
cellular	O
and	O
molecular	O
processes	O
which	O
are	O
involved	O
in	O
norrie	B-Disease
disease	I-Disease
(	O
nd	B-Disease
)	O
,	O
we	O
have	O
used	O
gene	O
targeting	O
technology	O
to	O
generate	O
nd	B-Disease
mutant	O
mice	O
.	O
	
the	O
murine	O
homologue	O
of	O
the	O
nd	B-Disease
gene	O
was	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
polypeptide	O
that	O
shares	O
94	O
%	O
of	O
the	O
amino	O
acid	O
sequence	O
with	O
its	O
human	O
counterpart	O
.	O
	
hemizygous	O
mice	O
carrying	O
a	O
replacement	O
mutation	O
in	O
exon	O
2	O
of	O
the	O
nd	B-Disease
gene	O
developed	O
retrolental	O
structures	O
in	O
the	O
vitreous	O
body	O
and	O
showed	O
an	O
overall	O
disorganization	O
of	O
the	O
retinal	O
ganglion	O
cell	O
layer	O
.	O
	
these	O
ocular	O
findings	O
are	O
consistent	O
with	O
observations	O
in	O
nd	B-Disease
patients	O
and	O
the	O
generated	O
mouse	O
line	O
provides	O
a	O
faithful	O
model	O
for	O
study	O
of	O
early	O
pathogenic	O
events	O
in	O
this	O
severe	O
x	B-Disease
-	I-Disease
linked	I-Disease
recessive	I-Disease
neurological	I-Disease
disorder	I-Disease
.	O
	
.	O
	
the	O
hybrid	O
pax3	O
-	O
fkhr	O
fusion	O
protein	O
of	O
alveolar	B-Disease
rhabdomyosarcoma	I-Disease
transforms	O
fibroblasts	O
in	O
culture	O
.	O
	
pediatric	B-Disease
alveolar	I-Disease
rhabdomyosarcoma	I-Disease
is	O
characterized	O
by	O
a	O
chromosomal	O
translocation	O
that	O
fuses	O
parts	O
of	O
the	O
pax3	O
and	O
fkhr	O
genes	O
.	O
	
somatic	O
-	O
cell	O
selection	O
is	O
a	O
major	O
determinant	O
of	O
the	O
blood	O
-	O
cell	O
phenotype	O
in	O
heterozygotes	O
for	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
mutations	O
causing	O
severe	O
enzyme	B-Disease
deficiency	I-Disease
.	O
	
in	O
most	O
people	O
with	O
red	O
-	O
blood	O
-	O
cell	O
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
(	I-Disease
g6pd	I-Disease
)	I-Disease
deficiency	I-Disease
,	O
the	O
enzyme	O
-	O
deficient	O
phenotype	O
is	O
only	O
moderately	O
expressed	O
in	O
nucleated	O
cells	O
.	O
	
however	O
,	O
in	O
a	O
small	O
subset	O
of	O
hemizygous	O
males	O
who	O
suffer	O
from	O
chronic	B-Disease
nonspherocytic	I-Disease
hemolytic	I-Disease
anemia	I-Disease
,	O
the	O
underlying	O
mutations	O
(	O
designated	O
class	O
i	O
)	O
cause	O
more	O
-	O
severe	O
g6pd	B-Disease
deficiency	I-Disease
,	O
and	O
this	O
might	O
provide	O
an	O
opportunity	O
for	O
selection	O
in	O
heterozygous	O
females	O
during	O
development	O
.	O
	
thus	O
,	O
it	O
appears	O
that	O
severe	O
g6pd	B-Disease
deficiency	I-Disease
affects	O
adversely	O
the	O
proliferation	O
or	O
the	O
survival	O
of	O
nucleated	O
blood	O
cells	O
and	O
that	O
this	O
phenotypic	O
characteristic	O
is	O
critical	O
during	O
hematopoiesis	O
.	O
	
.	O
	
analysis	O
of	O
meiotic	O
segregation	O
,	O
using	O
single	O
-	O
sperm	O
typing	O
:	O
meiotic	O
drive	O
at	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
locus	O
.	O
	
meiotic	O
drive	O
at	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
locus	O
has	O
recently	O
been	O
suggested	O
as	O
being	O
responsible	O
for	O
maintaining	O
the	O
frequency	O
,	O
in	O
the	O
human	O
population	O
,	O
of	O
dm	B-Disease
chromosomes	O
capable	O
of	O
expansion	O
to	O
the	O
disease	O
state	O
.	O
	
in	O
order	O
to	O
test	O
this	O
hypothesis	O
,	O
we	O
have	O
studied	O
samples	O
of	O
single	O
sperm	O
from	O
three	O
individuals	O
heterozygous	O
at	O
the	O
dm	B-Disease
locus	O
,	O
each	O
with	O
one	O
allele	O
larger	O
and	O
one	O
allele	O
smaller	O
than	O
19	O
ctg	O
repeats	O
.	O
	
to	O
guard	O
against	O
the	O
possible	O
problem	O
of	O
differential	O
pcr	O
amplification	O
rates	O
based	O
on	O
the	O
lengths	O
of	O
the	O
alleles	O
,	O
the	O
sperm	O
were	O
also	O
typed	O
at	O
another	O
closely	O
linked	O
marker	O
whose	O
allele	O
size	O
was	O
unrelated	O
to	O
the	O
allele	O
size	O
at	O
the	O
dm	B-Disease
locus	O
.	O
	
this	O
suggests	O
that	O
any	O
greater	O
amount	O
of	O
segregation	O
distortion	O
at	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
locus	O
must	O
result	O
from	O
events	O
following	O
sperm	O
ejaculation	O
.	O
	
lpp	O
,	O
the	O
preferred	O
fusion	O
partner	O
gene	O
of	O
hmgic	O
in	O
lipomas	B-Disease
,	O
is	O
a	O
novel	O
member	O
of	O
the	O
lim	O
protein	O
gene	O
family	O
.	O
	
a	O
major	O
cytogenetic	O
subgroup	O
of	O
lipomas	B-Disease
is	O
characterized	O
by	O
recurrent	O
chromosome	O
aberrations	O
,	O
mainly	O
translocations	O
,	O
that	O
involve	O
chromosome	O
segment	O
12q13	O
-	O
q15	O
.	O
	
here	O
,	O
we	O
report	O
the	O
identification	O
and	O
characterization	O
of	O
the	O
chromosome	O
3	O
-	O
derived	O
translocation	O
partner	O
gene	O
,	O
which	O
we	O
have	O
designated	O
lpp	O
(	O
lipoma	B-Disease
preferred	O
partner	O
gene	O
)	O
.	O
	
using	O
3	O
-	O
race	O
analysis	O
of	O
hmgic	O
fusion	O
transcripts	O
in	O
lipoma	B-Disease
cell	O
line	O
li	O
-	O
501	O
/	O
sv40	O
,	O
ectopic	O
genetic	O
sequences	O
were	O
obtained	O
,	O
which	O
by	O
cash	O
(	O
chromosome	O
assignment	O
using	O
somatic	O
cell	O
hybrids	O
)	O
and	O
fish	O
(	O
fluorescence	O
in	O
situ	O
hybridization	O
)	O
analysis	O
were	O
found	O
to	O
originate	O
from	O
chromosome	O
segment	O
3q27	O
-	O
q28	O
.	O
	
using	O
reverse	O
transcriptase	O
combined	O
with	O
polymerase	O
chain	O
reactions	O
in	O
the	O
analysis	O
of	O
a	O
number	O
of	O
lipoma	B-Disease
cell	O
lines	O
and	O
primary	B-Disease
lipomas	I-Disease
,	O
it	O
appeared	O
that	O
lpp	O
is	O
frequently	O
rearranged	O
also	O
in	O
cases	O
without	O
a	O
cytogenetically	O
detectable	O
involvement	O
of	O
3q27	O
-	O
q28	O
.	O
	
absence	O
of	O
disease	O
phenotype	O
and	O
intergenerational	O
stability	O
of	O
the	O
cag	O
repeat	O
in	O
transgenic	O
mice	O
expressing	O
the	O
human	O
huntington	B-Disease
disease	I-Disease
transcript	O
.	O
	
the	O
mutation	O
underlying	O
huntington	B-Disease
disease	I-Disease
(	O
hd	B-Disease
)	O
is	O
cag	O
expansion	O
in	O
the	O
first	O
exon	O
of	O
the	O
hd	B-Disease
gene	O
.	O
	
in	O
order	O
to	O
investigate	O
the	O
role	O
of	O
cag	O
expansion	O
in	O
the	O
pathogenesis	O
of	O
hd	B-Disease
,	O
we	O
have	O
produced	O
transgenic	O
mice	O
containing	O
the	O
full	O
length	O
human	O
hd	B-Disease
cdna	O
with	O
44	O
cag	O
repeats	O
.	O
	
by	O
1	O
year	O
,	O
these	O
mice	O
have	O
no	O
behavioral	B-Disease
abnormalities	I-Disease
and	O
morphometric	O
analysis	O
at	O
6	O
(	O
one	O
animal	O
)	O
and	O
9	O
(	O
two	O
animals	O
)	O
months	O
age	O
revealed	O
no	O
changes	O
.	O
	
despite	O
high	O
levels	O
of	O
mrna	O
expression	O
,	O
there	O
was	O
no	O
evidence	O
of	O
the	O
hd	B-Disease
gene	O
product	O
in	O
any	O
of	O
these	O
transgenic	O
mice	O
.	O
	
in	O
vitro	O
transfection	O
studies	O
indicated	O
that	O
the	O
inclusion	O
of	O
120	O
bp	O
of	O
the	O
5	O
utr	O
in	O
the	O
cdna	O
construct	O
and	O
the	O
presence	O
of	O
a	O
frameshift	O
mutation	O
at	O
nucleotide	O
2349	O
prevented	O
expression	O
of	O
the	O
hd	B-Disease
cdna	O
.	O
	
these	O
findings	O
suggest	O
that	O
the	O
pathogenesis	O
of	O
hd	B-Disease
is	O
not	O
mediated	O
through	O
dna	O
-	O
protein	O
interaction	O
and	O
that	O
presence	O
of	O
the	O
rna	O
transcript	O
with	O
an	O
expanded	O
cag	O
repeat	O
is	O
insufficient	O
to	O
cause	O
the	O
disease	O
.	O
	
rather	O
,	O
translation	O
of	O
the	O
cag	O
is	O
crucial	O
for	O
the	O
pathogenesis	O
of	O
hd	B-Disease
.	O
	
fish	O
studies	O
in	O
a	O
patient	O
with	O
sporadic	B-Disease
aniridia	I-Disease
and	O
t	O
(	O
7	O
;	O
11	O
)	O
(	O
q31	O
.	O
	
2	O
;	O
p13	O
)	O
.	O
	
a	O
2	O
year	O
old	O
female	O
presenting	O
with	O
bilateral	B-Disease
sporadic	I-Disease
aniridia	I-Disease
was	O
found	O
to	O
have	O
an	O
apparently	O
balanced	O
reciprocal	O
translocation	O
with	O
a	O
chromosome	O
11	O
breakpoint	O
within	O
band	O
p13	O
.	O
	
fluorescence	O
in	O
situ	O
hybridisation	O
(	O
fish	O
)	O
studies	O
with	O
distal	O
11p13	O
specific	O
cosmids	O
showed	O
that	O
the	O
chromosome	O
11	O
breakpoint	O
lay	O
between	O
the	O
aniridia	B-Disease
(	O
pax6	O
)	O
locus	O
and	O
a	O
region	O
approximately	O
100	O
kb	O
distal	O
to	O
pax6	O
defined	O
by	O
the	O
cosmid	O
fo2121	O
.	O
	
although	O
this	O
patient	O
did	O
not	O
have	O
a	O
detectable	O
deletion	O
within	O
pax6	O
,	O
her	O
aniridia	B-Disease
may	O
have	O
resulted	O
from	O
a	O
disruption	O
of	O
the	O
distal	O
chromatin	O
domain	O
containing	O
either	O
enhancers	O
or	O
regulators	O
for	O
pax6	O
.	O
	
this	O
case	O
may	O
therefore	O
be	O
another	O
example	O
of	O
aniridia	B-Disease
caused	O
by	O
a	O
position	O
effect	O
as	O
recently	O
described	O
in	O
two	O
familial	B-Disease
aniridia	I-Disease
patients	O
in	O
which	O
the	O
phenotype	O
cosegregated	O
with	O
chromosome	B-Disease
abnormalities	I-Disease
with	O
11p13	O
breakpoints	O
.	O
	
.	O
	
muscle	O
expression	O
of	O
glucose	B-Disease
-	I-Disease
6	I-Disease
-	I-Disease
phosphate	I-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
in	O
different	O
variants	O
.	O
	
muscle	O
expression	O
of	O
g6pd	B-Disease
deficiency	I-Disease
has	O
been	O
investigated	O
in	O
mediterranean	O
,	O
seattle	O
-	O
like	O
and	O
a	O
-	O
variants	O
.	O
	
gene	O
therapy	O
for	O
phenylketonuria	B-Disease
.	O
	
classical	O
phenylketonuria	B-Disease
(	O
pku	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
caused	O
by	O
a	O
deficiency	B-Disease
of	I-Disease
hepatic	I-Disease
phenylalanine	I-Disease
hydroxylase	I-Disease
(	O
pah	O
)	O
.	O
	
limitations	O
of	O
the	O
current	O
dietary	O
treatment	O
for	O
pku	B-Disease
have	O
led	O
to	O
the	O
development	O
of	O
potential	O
treatments	O
based	O
on	O
somatic	O
gene	O
transfer	O
.	O
	
vectors	O
derived	O
from	O
a	O
recombinant	O
retrovirus	O
or	O
a	O
dna	O
/	O
protein	O
complex	O
can	O
efficiently	O
transduce	O
the	O
pah	O
cdna	O
into	O
pah	B-Disease
-	I-Disease
deficient	I-Disease
hepatocytes	O
in	O
vitro	O
,	O
but	O
the	O
application	O
of	O
these	O
vector	O
systems	O
is	O
presently	O
limited	O
by	O
their	O
low	O
transduction	O
efficiency	O
in	O
vivo	O
.	O
	
in	O
contrast	O
,	O
a	O
vector	O
derived	O
from	O
a	O
recombinant	O
adenovirus	O
can	O
restore	O
10	O
%	O
-	O
80	O
%	O
of	O
normal	O
hepatic	O
pah	O
activity	O
into	O
pah	B-Disease
-	I-Disease
deficient	I-Disease
mice	O
,	O
which	O
completely	O
normalizes	O
serum	O
phenylalanine	O
levels	O
.	O
	
however	O
,	O
these	O
findings	O
suggest	O
that	O
pku	B-Disease
can	O
be	O
completely	O
corrected	O
by	O
somatic	O
gene	O
therapy	O
,	O
and	O
provide	O
some	O
direction	O
for	O
the	O
future	O
development	O
of	O
adenoviral	O
vectors	O
.	O
	
.	O
	
the	O
human	O
neuronal	O
nicotinic	O
acetylcholine	O
receptor	O
alpha	O
4	O
subunit	O
gene	O
(	O
chrna4	O
)	O
is	O
located	O
in	O
the	O
candidate	O
region	O
for	O
three	O
different	O
phenotypes	O
benign	B-Disease
familial	I-Disease
neonatal	I-Disease
convulsions	I-Disease
,	O
autosomal	B-Disease
dominant	I-Disease
nocturnal	I-Disease
frontal	I-Disease
lobe	I-Disease
epilepsy	I-Disease
,	O
and	O
low	O
-	O
voltage	O
eeg	O
.	O
	
recently	O
,	O
a	O
missense	O
mutation	O
in	O
transmembrane	O
domain	O
2	O
of	O
chrna4	O
was	O
found	O
to	O
be	O
associated	O
with	O
autosomal	B-Disease
dominant	I-Disease
nocturnal	I-Disease
frontal	I-Disease
lobe	I-Disease
epilepsy	I-Disease
in	O
one	O
extended	O
pedigree	O
.	O
	
the	O
sequence	O
analysis	O
provides	O
the	O
basis	O
for	O
a	O
comprehensive	O
mutation	O
screening	O
of	O
chrna4	O
in	O
the	O
above	O
-	O
mentioned	O
phenotypes	O
and	O
possibly	O
in	O
other	O
types	O
of	O
idiopathic	B-Disease
epilepsies	I-Disease
.	O
	
.	O
	
brca1	O
and	O
brca2	O
are	O
the	O
two	O
major	O
identified	O
causes	O
of	O
inherited	B-Disease
breast	I-Disease
cancer	I-Disease
,	O
with	O
mutations	O
in	O
either	O
gene	O
conferring	O
up	O
to	O
80	O
-	O
90	O
%	O
lifetime	O
risk	O
of	O
breast	B-Disease
cancer	I-Disease
in	O
carrier	O
females	O
.	O
	
mutations	O
in	O
brca1	O
account	O
for	O
approximately	O
45	O
%	O
of	O
familial	B-Disease
breast	I-Disease
cancer	I-Disease
and	O
90	O
%	O
of	O
inherited	B-Disease
breast	I-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
,	O
whereas	O
mutations	O
in	O
brca2	O
account	O
for	O
a	O
comparable	O
percentage	O
of	O
inherited	B-Disease
breast	I-Disease
cancer	I-Disease
cases	O
.	O
	
the	O
6174delt	O
mutation	O
in	O
brca2	O
was	O
recently	O
identified	O
as	O
a	O
frequent	O
mutation	O
in	O
8	O
out	O
of	O
107	O
ashkenazi	O
jewish	O
women	O
diagnosed	O
with	O
breast	B-Disease
cancer	I-Disease
by	O
age	O
50	O
(	O
ref	O
.	O
	
8	O
)	O
,	O
as	O
well	O
as	O
in	O
three	O
ashkenazi	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
patients	O
.	O
	
we	O
have	O
conducted	O
a	O
large	O
-	O
scale	O
population	O
study	O
to	O
investigate	O
the	O
prevalence	O
of	O
specific	O
brca1	O
and	O
brca2	O
mutations	O
in	O
ashkenazi	O
jewish	O
individuals	O
who	O
were	O
unselected	O
for	O
breast	B-Disease
cancer	I-Disease
.	O
	
this	O
expanded	O
population	O
-	O
based	O
study	O
confirms	O
that	O
the	O
brca1	O
185delag	O
mutation	O
and	O
the	O
brca2	O
6174delt	O
mutation	O
constitute	O
the	O
two	O
most	O
frequent	O
mutation	O
alleles	O
predisposing	O
to	O
hereditary	B-Disease
breast	I-Disease
cancer	I-Disease
among	O
the	O
ashkenazim	O
,	O
and	O
suggests	O
a	O
relatively	O
lower	O
penetrance	O
for	O
the	O
6174delt	O
mutation	O
in	O
brca2	O
the	O
gene	O
mutated	O
in	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
at	B-Disease
)	O
patients	O
,	O
denoted	O
atm	O
,	O
encodes	O
a	O
putative	O
protein	O
or	O
lipid	O
kinase	O
.	O
	
consistent	O
with	O
cellular	O
defects	O
of	O
at	B-Disease
patients	O
,	O
the	O
atm	O
-	O
/	O
-	O
cells	O
are	O
hypersensitive	O
to	O
gamma	O
-	O
irradiation	O
and	O
defective	O
in	O
cell	O
-	O
cycle	O
arrest	O
following	O
radiation	O
,	O
correlating	O
with	O
a	O
defective	O
up	O
-	O
regulation	O
of	O
p53	O
.	O
	
atm	O
+	O
/	O
-	O
fibroblasts	O
and	O
thymocytes	O
showed	O
intermediately	O
defective	O
responses	O
to	O
irradiation	O
but	O
no	O
growth	O
defect	O
,	O
suggesting	O
that	O
the	O
increased	O
cancer	B-Disease
risk	O
of	O
at	B-Disease
heterozygotes	O
could	O
be	O
attributable	O
to	O
poor	O
checkpoint	O
function	O
.	O
	
.	O
	
targeted	O
disruption	O
of	O
atm	O
leads	O
to	O
growth	B-Disease
retardation	I-Disease
,	O
chromosomal	B-Disease
fragmentation	I-Disease
during	I-Disease
meiosis	I-Disease
,	O
immune	B-Disease
defects	I-Disease
,	O
and	O
thymic	B-Disease
lymphoma	I-Disease
.	O
	
atm	O
,	O
the	O
gene	O
mutated	O
in	O
the	O
inherited	B-Disease
human	I-Disease
disease	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
,	O
is	O
a	O
member	O
of	O
a	O
family	O
of	O
kinases	O
involved	O
in	O
dna	O
metabolism	O
and	O
cell	O
-	O
cycle	O
checkpoint	O
control	O
.	O
	
initial	O
evaluation	O
of	O
the	O
atm	O
knockout	O
animals	O
indicates	O
that	O
inactivation	O
of	O
the	O
mouse	O
atm	O
gene	O
recreates	O
much	O
of	O
the	O
phenotype	O
of	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
.	O
	
the	O
infertility	B-Disease
of	O
atm	O
-	O
/	O
-	O
mice	O
results	O
from	O
meiotic	O
failure	O
.	O
	
immune	B-Disease
defects	I-Disease
also	O
are	O
evident	O
in	O
atm	O
-	O
/	O
-	O
mice	O
,	O
including	O
reduced	O
numbers	O
of	O
b220	O
+	O
cd43	O
-	O
pre	O
-	O
b	O
cells	O
,	O
thymocytes	O
,	O
and	O
peripheral	O
t	O
cells	O
,	O
as	O
well	O
as	O
functional	O
impairment	O
of	O
t	O
-	O
cell	O
-	O
dependent	O
immune	O
responses	O
.	O
	
the	O
cerebella	O
of	O
atm	O
-	O
/	O
-	O
mice	O
appear	O
normal	O
by	O
histologic	O
examination	O
at	O
3	O
to	O
4	O
months	O
and	O
the	O
mice	O
have	O
no	O
gross	O
behavioral	B-Disease
abnormalities	I-Disease
.	O
	
the	O
majority	O
of	O
mutant	O
mice	O
rapidly	O
develop	O
thymic	B-Disease
lymphomas	I-Disease
and	O
die	O
before	O
4	O
months	O
of	O
age	O
.	O
	
these	O
findings	O
indicate	O
that	O
the	O
atm	O
gene	O
product	O
plays	O
an	O
essential	O
role	O
in	O
a	O
diverse	O
group	O
of	O
cellular	O
processes	O
,	O
including	O
meiosis	O
,	O
the	O
normal	O
growth	O
of	O
somatic	O
tissues	O
,	O
immune	O
development	O
,	O
and	O
tumor	B-Disease
suppression	O
.	O
	
.	O
	
this	O
agrees	O
well	O
with	O
the	O
fact	O
that	O
cardiac	O
and	O
muscle	O
symptoms	O
are	O
characteristic	O
for	O
patients	O
with	O
vlcad	B-Disease
deficiency	I-Disease
.	O
	
northern	O
blot	O
analysis	O
and	O
sequencing	O
of	O
cloned	O
pcr	O
amplified	O
vlcad	O
cdna	O
from	O
four	O
unrelated	O
patients	O
with	O
vlcad	B-Disease
deficiency	I-Disease
showed	O
that	O
vlcad	O
mrna	O
was	O
undetectable	O
in	O
one	O
patient	O
and	O
that	O
the	O
other	O
three	O
have	O
mutations	O
in	O
both	O
vlcad	O
alleles	O
.	O
	
molecular	O
bases	O
of	O
combined	B-Disease
subtotal	I-Disease
deficiencies	I-Disease
of	I-Disease
c6	I-Disease
and	I-Disease
c7	I-Disease
:	O
their	O
effects	O
in	O
combination	O
with	O
other	O
c6	B-Disease
and	I-Disease
c7	I-Disease
deficiencies	I-Disease
.	O
	
combined	B-Disease
subtotal	I-Disease
deficiency	I-Disease
of	I-Disease
c6	I-Disease
and	I-Disease
c7	I-Disease
,	O
in	O
which	O
both	O
proteins	O
are	O
expressed	O
at	O
very	O
low	O
levels	O
,	O
has	O
been	O
observed	O
in	O
homozygous	O
form	O
in	O
two	O
families	O
.	O
	
the	O
haplotype	O
has	O
been	O
found	O
in	O
combination	O
with	O
a	O
number	O
of	O
other	O
haplotypes	O
containing	O
defective	O
genes	O
that	O
lead	O
either	O
to	O
c6	B-Disease
or	I-Disease
c7	I-Disease
deficiency	I-Disease
,	O
but	O
with	O
different	O
consequences	O
.	O
	
where	O
it	O
is	O
combined	O
with	O
a	O
c6	B-Disease
-	I-Disease
deficient	I-Disease
gene	O
,	O
the	O
serum	O
c7	O
levels	O
can	O
be	O
surprisingly	O
high	O
,	O
possibly	O
because	O
there	O
is	O
no	O
c6	O
generating	O
c56	O
to	O
consume	O
the	O
c7	O
.	O
	
genetic	O
bases	O
of	O
human	O
complement	B-Disease
c7	I-Disease
deficiency	I-Disease
.	O
	
complement	B-Disease
c7	I-Disease
deficiency	I-Disease
(	O
c7d	B-Disease
)	O
is	O
associated	O
frequently	O
with	O
recurrent	O
bacterial	B-Disease
infections	I-Disease
,	O
especially	O
meningitis	B-Disease
caused	O
by	O
neisseria	B-Disease
meningitidis	I-Disease
.	O
	
we	O
report	O
in	O
this	O
work	O
the	O
molecular	O
bases	O
of	O
c7d	B-Disease
in	O
two	O
unrelated	O
japanese	O
males	O
.	O
	
moreover	O
,	O
we	O
detected	O
a	O
novel	O
polymorphism	O
in	O
intron	O
11	O
that	O
presumably	O
is	O
linked	O
to	O
the	O
mutation	O
responsible	O
for	O
c7d	B-Disease
in	O
case	O
1	O
.	O
	
our	O
results	O
indicate	O
that	O
the	O
pathogenesis	O
of	O
c7d	B-Disease
is	O
heterogeneous	O
like	O
most	O
of	O
the	O
other	O
deficiencies	B-Disease
of	I-Disease
complement	I-Disease
components	I-Disease
.	O
	
.	O
	
hprt	B-Disease
-	I-Disease
aprt	I-Disease
-	I-Disease
deficient	I-Disease
mice	O
are	O
not	O
a	O
model	O
for	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
.	O
	
complete	B-Disease
hypoxanthine	I-Disease
-	I-Disease
guanine	I-Disease
phosphoribosyl	I-Disease
-	I-Disease
transferase	I-Disease
(	I-Disease
hprt	I-Disease
)	I-Disease
deficiency	I-Disease
in	O
humans	O
results	O
in	O
the	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
which	O
is	O
characterized	O
,	O
among	O
other	O
features	O
,	O
by	O
compulsive	O
self	O
-	O
injurious	O
behavior	O
.	O
	
hprt	B-Disease
-	I-Disease
deficient	I-Disease
mice	O
generated	O
using	O
mouse	O
embryonic	O
stem	O
cells	O
exhibit	O
none	O
of	O
the	O
behavioral	O
symptoms	O
associated	O
with	O
the	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
.	O
	
administration	O
of	O
drugs	O
that	O
inhibit	O
adenine	O
phosphoribosyltransferase	O
(	O
aprt	O
)	O
in	O
hprt	B-Disease
-	I-Disease
deficient	I-Disease
mice	O
has	O
produced	O
the	O
suggestion	O
that	O
deficiency	B-Disease
of	I-Disease
aprt	I-Disease
in	O
combination	O
with	O
hprt	B-Disease
-	I-Disease
deficiency	I-Disease
in	O
mice	O
may	O
lead	O
to	O
self	O
-	O
mutilation	O
behavior	O
[	O
c	O
.	O
	
l	O
.	O
	
wu	O
and	O
d	O
.	O
	
w	O
.	O
	
melton	O
(	O
1993	O
)	O
nature	O
genet	O
.	O
	
3	O
,	O
235	O
-	O
240	O
]	O
.	O
	
to	O
test	O
this	O
proposition	O
,	O
we	O
bred	O
hprt	B-Disease
-	I-Disease
aprt	I-Disease
-	I-Disease
deficient	I-Disease
mice	O
.	O
	
although	O
the	O
doubly	O
-	O
deficient	O
mice	O
excrete	O
adenine	O
and	O
its	O
highly	O
insoluble	O
derivative	O
,	O
2	O
,	O
8	O
-	O
dihydroxyadenine	O
,	O
which	O
are	O
also	O
associated	O
with	O
human	O
aprt	B-Disease
deficiency	I-Disease
,	O
additional	O
abnormalities	O
or	O
any	O
self	O
-	O
injurious	O
behavior	O
were	O
not	O
detected	O
.	O
	
thus	O
,	O
aprt	B-Disease
-	I-Disease
hprt	I-Disease
-	I-Disease
deficient	I-Disease
mice	O
,	O
which	O
are	O
devoid	O
of	O
any	O
purine	O
salvage	O
pathways	O
,	O
show	O
no	O
novel	O
phenotype	O
and	O
are	O
not	O
a	O
model	O
for	O
the	O
behavioral	B-Disease
abnormalities	I-Disease
associated	O
with	O
the	O
lesch	B-Disease
-	I-Disease
nyhan	I-Disease
syndrome	I-Disease
as	O
previously	O
suggested	O
somatic	O
alterations	O
of	O
the	O
dpc4	O
gene	O
in	O
human	O
colorectal	B-Disease
cancers	I-Disease
in	O
vivo	O
.	O
	
background	O
&	O
aims	O
the	O
chromosome	O
region	O
18q21	O
has	O
been	O
shown	O
to	O
be	O
frequently	O
deleted	O
in	O
colorectal	B-Disease
cancers	I-Disease
,	O
and	O
such	O
frequent	O
allelic	O
loss	O
is	O
a	O
hallmark	O
of	O
the	O
presence	O
of	O
a	O
tumor	O
-	O
suppressor	O
gene	O
.	O
	
the	O
dpc4	O
gene	O
,	O
which	O
is	O
located	O
at	O
18q21	O
,	O
has	O
been	O
identified	O
as	O
a	O
tumor	O
-	O
suppressor	O
gene	O
from	O
examination	O
of	O
pancreatic	B-Disease
cancers	I-Disease
.	O
	
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
it	O
might	O
also	O
be	O
altered	O
in	O
colorectal	B-Disease
cancers	I-Disease
.	O
	
methods	O
mutation	O
analyses	O
of	O
the	O
dpc4	O
gene	O
were	O
performed	O
on	O
complementary	O
dna	O
samples	O
from	O
31	O
primary	O
colorectal	B-Disease
cancer	I-Disease
specimens	O
using	O
a	O
combination	O
of	O
polymerase	O
chain	O
reaction	O
,	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
,	O
and	O
dna	O
sequencing	O
.	O
	
results	O
four	O
missense	O
mutations	O
producing	O
amino	O
acid	O
substitutions	O
and	O
a	O
somatic	O
12	O
-	O
base	O
pair	O
deletion	O
in	O
the	O
coding	O
region	O
of	O
the	O
dpc4	O
gene	O
were	O
detected	O
in	O
the	O
31	O
cancers	B-Disease
(	O
16	O
%	O
;	O
5	O
of	O
31	O
)	O
.	O
	
conclusions	O
the	O
dpc4	O
gene	O
may	O
play	O
a	O
role	O
as	O
a	O
tumor	O
-	O
suppressor	O
gene	O
in	O
a	O
fraction	O
of	O
colorectal	B-Disease
cancers	I-Disease
;	O
however	O
,	O
while	O
allelic	O
loss	O
at	O
18q21	O
is	O
very	O
often	O
seen	O
in	O
colorectal	B-Disease
cancers	I-Disease
,	O
only	O
a	O
minority	O
show	O
dpc4	O
mutations	O
,	O
suggesting	O
that	O
there	O
might	O
be	O
another	O
tumor	O
-	O
suppressor	O
gene	O
in	O
this	O
chromosome	O
region	O
.	O
	
.	O
	
pleiotropic	O
defects	O
in	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
protein	O
-	O
deficient	O
mice	O
.	O
	
we	O
have	O
generated	O
a	O
mouse	O
model	O
for	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
by	O
using	O
gene	O
targeting	O
to	O
generate	O
mice	O
that	O
do	O
not	O
express	O
the	O
atm	O
protein	O
.	O
	
atm	O
-	O
deficient	O
mice	O
are	O
retarded	O
in	O
growth	O
,	O
do	O
not	O
produce	O
mature	O
sperm	O
,	O
and	O
exhibit	O
severe	O
defects	O
in	O
t	O
cell	O
maturation	O
while	O
going	O
on	O
to	O
develop	O
thymomas	B-Disease
.	O
	
atm	O
-	O
deficient	O
mice	O
then	O
exhibit	O
many	O
of	O
the	O
same	O
symptoms	O
found	O
in	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
patients	O
and	O
in	O
cells	O
derived	O
from	O
them	O
.	O
	
the	O
dcc	O
protein	O
and	O
prognosis	O
in	O
colorectal	B-Disease
cancer	I-Disease
.	O
	
background	O
allelic	O
loss	O
of	O
chromosome	O
18q	O
predicts	O
a	O
poor	O
outcome	O
in	O
patients	O
with	O
stage	B-Disease
ii	I-Disease
colorectal	I-Disease
cancer	I-Disease
.	O
	
although	O
the	O
specific	O
gene	O
inactivated	O
by	O
this	O
allelic	O
loss	O
has	O
not	O
been	O
elucidated	O
,	O
the	O
dcc	O
(	O
deleted	O
in	O
colorectal	B-Disease
cancer	I-Disease
)	O
gene	O
is	O
a	O
candidate	O
.	O
	
we	O
investigated	O
whether	O
the	O
expression	O
of	O
the	O
dcc	O
protein	O
in	O
tumor	B-Disease
cells	O
is	O
a	O
prognostic	O
marker	O
in	O
colorectal	B-Disease
carcinoma	I-Disease
.	O
	
methods	O
the	O
expression	O
of	O
dcc	O
was	O
evaluated	O
immunohistochemically	O
in	O
132	O
paraffin	O
-	O
embedded	O
samples	O
from	O
patients	O
with	O
curatively	O
resected	O
stage	B-Disease
ii	I-Disease
and	I-Disease
iii	I-Disease
colorectal	I-Disease
carcinomas	I-Disease
.	O
	
the	O
cox	O
proportional	O
-	O
hazards	O
model	O
was	O
used	O
to	O
adjust	O
for	O
covariates	O
including	O
age	O
,	O
sex	O
,	O
tumor	B-Disease
site	O
,	O
degree	O
of	O
tumor	B-Disease
differentiation	O
,	O
and	O
use	O
of	O
adjuvant	O
therapy	O
.	O
	
results	O
the	O
expression	O
of	O
dcc	O
was	O
a	O
strong	O
positive	O
predictive	O
factor	O
for	O
survival	O
in	O
both	O
stage	B-Disease
ii	I-Disease
and	I-Disease
stage	I-Disease
iii	I-Disease
colorectal	I-Disease
carcinomas	I-Disease
.	O
	
in	O
patients	O
with	O
stage	O
ii	O
disease	O
whose	O
tumors	B-Disease
expressed	O
dcc	O
,	O
the	O
five	O
-	O
year	O
survival	O
rate	O
was	O
94	O
.	O
	
3	O
percent	O
,	O
whereas	O
in	O
patients	O
with	O
dcc	B-Disease
-	I-Disease
negative	I-Disease
tumors	I-Disease
,	O
the	O
survival	O
rate	O
was	O
61	O
.	O
	
in	O
patients	O
with	O
stage	B-Disease
iii	I-Disease
disease	I-Disease
,	O
the	O
respective	O
survival	O
rates	O
were	O
59	O
.	O
	
conclusions	O
dcc	O
is	O
a	O
prognostic	O
marker	O
in	O
patients	O
with	O
stage	B-Disease
ii	I-Disease
or	I-Disease
stage	I-Disease
iii	I-Disease
colorectal	I-Disease
cancer	I-Disease
.	O
	
in	O
stage	B-Disease
ii	I-Disease
colorectal	I-Disease
carcinomas	I-Disease
,	O
the	O
absence	O
of	O
dcc	O
identifies	O
a	O
subgroup	O
of	O
patients	O
with	O
lesions	O
that	O
behave	O
like	O
stage	B-Disease
iii	I-Disease
cancers	I-Disease
.	O
	
association	O
of	O
anxiety	B-Disease
-	I-Disease
related	I-Disease
traits	I-Disease
with	O
a	O
polymorphism	O
in	O
the	O
serotonin	O
transporter	O
gene	O
regulatory	O
region	O
.	O
	
transporter	O
-	O
facilitated	O
uptake	O
of	O
serotonin	O
(	O
5	O
-	O
hydroxytryptamine	O
or	O
5	O
-	O
ht	O
)	O
has	O
been	O
implicated	O
in	O
anxiety	B-Disease
in	O
humans	O
and	O
animal	O
models	O
and	O
is	O
the	O
site	O
of	O
action	O
of	O
widely	O
used	O
uptake	O
-	O
inhibiting	O
antidepressant	O
and	O
antianxiety	O
drugs	O
.	O
	
association	O
studies	O
in	O
two	O
independent	O
samples	O
totaling	O
505	O
individuals	O
revealed	O
that	O
the	O
5	O
-	O
htt	O
polymorphism	O
accounts	O
for	O
3	O
to	O
4	O
percent	O
of	O
total	O
variation	O
and	O
7	O
to	O
9	O
percent	O
of	O
inherited	O
variance	O
in	O
anxiety	B-Disease
-	I-Disease
related	I-Disease
personality	I-Disease
traits	I-Disease
in	O
individuals	O
as	O
well	O
as	O
sibships	O
.	O
	
.	O
	
phenotypic	O
and	O
genotypic	O
overlap	O
between	O
atelosteogenesis	B-Disease
type	I-Disease
2	I-Disease
and	O
diastrophic	B-Disease
dysplasia	I-Disease
.	O
	
mutations	O
in	O
the	O
diastrophic	B-Disease
dysplasia	I-Disease
sulfate	O
transporter	O
gene	O
dtdst	O
have	O
been	O
associated	O
with	O
a	O
family	O
of	O
chondrodysplasias	B-Disease
that	O
comprises	O
,	O
in	O
order	O
of	O
increasing	O
severity	O
,	O
diastrophic	B-Disease
dysplasia	I-Disease
(	O
dtd	B-Disease
)	O
,	O
atelosteogenesis	B-Disease
type	I-Disease
2	I-Disease
(	O
ao2	B-Disease
)	O
,	O
and	O
achondrogenesis	B-Disease
type	I-Disease
1b	I-Disease
(	O
acg1b	B-Disease
)	O
.	O
	
to	O
learn	O
more	O
about	O
the	O
molecular	O
basis	O
of	O
dtdst	B-Disease
chondrodysplasias	I-Disease
and	O
about	O
genotype	O
-	O
phenotype	O
correlations	O
,	O
we	O
studied	O
fibroblast	O
cultures	O
of	O
three	O
new	O
patients	O
one	O
with	O
ao	B-Disease
-	I-Disease
2	I-Disease
,	O
one	O
with	O
dtd	B-Disease
,	O
and	O
one	O
with	O
an	O
intermediate	O
phenotype	O
(	O
ao2	B-Disease
/	O
dtd	B-Disease
)	O
.	O
	
in	O
two	O
patients	O
(	O
dtd	B-Disease
and	O
ao2	B-Disease
/	O
dtd	B-Disease
)	O
,	O
no	O
other	O
structural	O
mutation	O
was	O
found	O
,	O
but	O
polymerase	O
chain	O
reaction	O
amplification	O
and	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
of	O
fibroblast	O
cdna	O
showed	O
reduced	O
mrna	O
levels	O
of	O
the	O
wild	O
-	O
type	O
dtdst	O
allele	O
these	O
two	O
patients	O
may	O
be	O
compound	O
heterozygotes	O
for	O
the	O
finnish	O
mutation	O
(	O
as	O
yet	O
uncharacterized	O
at	O
the	O
dna	O
level	O
)	O
,	O
which	O
causes	O
reduced	O
expression	O
of	O
dtdst	O
.	O
	
the	O
third	O
patient	O
(	O
with	O
ao2	B-Disease
)	O
had	O
the	O
r279w	O
mutation	O
compounded	O
with	O
a	O
novel	O
mutation	O
,	O
the	O
deletion	O
of	O
cytosine	O
418	O
(	O
delta	O
c418	O
)	O
,	O
predicting	O
a	O
frameshift	O
with	O
premature	O
termination	O
.	O
	
the	O
presence	O
of	O
the	O
dtdst	O
r279w	O
mutation	O
in	O
a	O
total	O
of	O
11	O
patients	O
with	O
ao2	B-Disease
or	O
dtd	B-Disease
emphasizes	O
the	O
overlap	O
between	O
these	O
conditions	O
.	O
	
this	O
mutation	O
has	O
not	O
been	O
found	O
so	O
far	O
in	O
8	O
analyzed	O
acg1b	B-Disease
patients	O
,	O
suggesting	O
that	O
it	O
allows	O
some	O
residual	O
activity	O
of	O
the	O
sulfate	O
transporter	O
.	O
	
.	O
	
identification	O
of	O
wasp	O
mutations	O
,	O
mutation	O
hotspots	O
and	O
genotype	O
-	O
phenotype	O
disparities	O
in	O
24	O
patients	O
with	O
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
.	O
	
the	O
wiskott	B-Disease
-	I-Disease
aldrich	I-Disease
syndrome	I-Disease
(	O
was	B-Disease
)	O
,	O
an	O
x	B-Disease
-	I-Disease
linked	I-Disease
immunodeficiency	I-Disease
disease	I-Disease
caused	O
by	O
mutation	O
in	O
the	O
recently	O
isolated	O
gene	O
encoding	O
was	B-Disease
protein	O
(	O
wasp	O
)	O
,	O
is	O
known	O
to	O
be	O
associated	O
with	O
extensive	O
clinical	O
heterogeneity	O
.	O
	
cumulative	O
mutation	O
data	O
have	O
revealed	O
that	O
wasp	O
genotypes	O
are	O
also	O
highly	O
variable	O
among	O
was	B-Disease
patients	O
,	O
but	O
the	O
relationship	O
of	O
phenotype	O
with	O
genotype	O
in	O
this	O
disease	O
remains	O
unclear	O
.	O
	
to	O
address	O
this	O
issue	O
we	O
characterized	O
wasp	O
mutations	O
in	O
24	O
unrelated	O
was	B-Disease
patients	O
,	O
including	O
18	O
boys	O
with	O
severe	O
classical	O
was	B-Disease
and	O
6	O
boys	O
expressing	O
mild	O
forms	O
of	O
the	O
disease	O
,	O
and	O
then	O
examined	O
the	O
degree	O
of	O
correlation	O
of	O
these	O
as	O
well	O
as	O
all	O
previously	O
published	O
wasp	O
mutations	O
with	O
disease	O
severity	O
.	O
	
similarly	O
,	O
while	O
the	O
cumulative	O
data	O
revealed	O
a	O
predominance	O
of	O
missense	O
mutations	O
among	O
the	O
wasp	O
gene	O
lesions	O
observed	O
in	O
boys	O
with	O
isolated	B-Disease
thrombocytopenia	I-Disease
,	O
missense	O
mutations	O
were	O
not	O
exclusively	O
associated	O
with	O
milder	O
was	B-Disease
phenotypes	O
,	O
but	O
also	O
comprised	O
a	O
substantial	O
portion	O
(	O
38	O
%	O
)	O
of	O
the	O
wasp	O
gene	O
defects	O
found	O
in	O
patients	O
with	O
severe	O
disease	O
.	O
	
these	O
findings	O
,	O
as	O
well	O
as	O
the	O
detection	O
of	O
identical	O
wasp	O
mutations	O
in	O
patients	O
with	O
disparate	O
phenotypes	O
,	O
reveal	O
a	O
lack	O
of	O
phenotype	O
concordance	O
with	O
genotype	O
in	O
was	B-Disease
and	O
thus	O
imply	O
that	O
phenotypic	O
outcome	O
in	O
this	O
disease	O
cannot	O
be	O
reliably	O
predicted	O
solely	O
on	O
the	O
basis	O
of	O
wasp	O
genotypes	O
.	O
	
.	O
	
germline	O
mutations	O
in	O
the	O
3	O
'	O
part	O
of	O
apc	B-Disease
exon	O
15	O
do	O
not	O
result	O
in	O
truncated	O
proteins	O
and	O
are	O
associated	O
with	O
attenuated	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
.	O
	
familial	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
(	O
fap	B-Disease
)	O
is	O
an	O
inherited	O
predisposition	O
to	O
colorectal	B-Disease
cancer	I-Disease
characterized	O
by	O
the	O
development	O
of	O
numerous	O
adenomatous	B-Disease
polyps	I-Disease
predominantly	O
in	O
the	O
colorectal	O
region	O
.	O
	
germline	O
mutations	O
in	O
the	O
adenomatous	B-Disease
polyposis	I-Disease
coli	I-Disease
(	O
apc	B-Disease
)	O
gene	O
are	O
responsible	O
for	O
most	O
cases	O
of	O
fap	B-Disease
.	O
	
mutations	O
at	O
the	O
5	O
end	O
of	O
apc	B-Disease
are	O
known	O
to	O
be	O
associated	O
with	O
a	O
relatively	O
mild	O
form	O
of	O
the	O
disease	O
,	O
called	O
attenuated	B-Disease
adenomatous	I-Disease
polyposis	I-Disease
coli	I-Disease
(	O
aapc	B-Disease
)	O
.	O
	
we	O
identified	O
a	O
frameshift	O
mutation	O
in	O
the	O
3	O
part	O
of	O
exon	O
15	O
,	O
resulting	O
in	O
a	O
stop	O
codon	O
at	O
1862	O
,	O
in	O
a	O
large	O
dutch	O
kindred	O
with	O
aapc	B-Disease
.	O
	
western	O
blot	O
analysis	O
of	O
lymphoblastoid	O
cell	O
lines	O
derived	O
from	O
affected	O
family	O
members	O
from	O
this	O
kindred	O
,	O
as	O
well	O
as	O
from	O
a	O
previously	O
reported	O
swiss	O
family	O
carrying	O
a	O
frameshift	O
mutation	O
at	O
codon	O
1987	O
and	O
displaying	O
a	O
similar	O
attenuated	O
phenotype	O
,	O
showed	O
only	O
the	O
wild	O
-	O
type	O
apc	B-Disease
protein	O
.	O
	
our	O
study	O
indicates	O
that	O
chain	O
-	O
terminating	O
mutations	O
located	O
in	O
the	O
3	O
part	O
of	O
apc	B-Disease
do	O
not	O
result	O
in	O
detectable	O
truncated	O
polypeptides	O
and	O
we	O
hypothesize	O
that	O
this	O
is	O
likely	O
to	O
be	O
the	O
basis	O
for	O
the	O
observed	O
aapc	B-Disease
phenotype	O
.	O
	
.	O
	
over	O
100	O
distinct	O
disease	O
-	O
associated	O
mutations	O
have	O
been	O
identified	O
in	O
the	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
susceptibility	O
gene	O
brca1	O
.	O
	
loss	O
of	O
the	O
wild	O
-	O
type	O
allele	O
in	O
>	O
90	O
%	O
of	O
tumors	B-Disease
from	O
patients	O
with	O
inherited	O
brca1	O
mutations	O
indicates	O
tumor	B-Disease
suppressive	O
function	O
.	O
	
the	O
low	O
incidence	O
of	O
somatic	O
mutations	O
suggests	O
that	O
brca1	O
inactivation	O
in	O
sporadic	O
tumors	B-Disease
occurs	O
by	O
alternative	O
mechanisms	O
,	O
such	O
as	O
interstitial	O
chromosomal	O
deletion	O
or	O
reduced	O
transcription	O
.	O
	
the	O
hereditary	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
gene	O
,	O
brca1	O
,	O
encodes	O
a	O
large	O
polypeptide	O
that	O
contains	O
the	O
cysteine	O
-	O
rich	O
ring	O
motif	O
,	O
a	O
zinc	O
-	O
binding	O
domain	O
found	O
in	O
a	O
variety	O
of	O
regulatory	O
proteins	O
.	O
	
the	O
bard1	O
/	O
brca1	O
interaction	O
is	O
disrupted	O
by	O
brca1	O
missense	O
mutations	O
that	O
segregate	O
with	O
breast	B-Disease
cancer	I-Disease
susceptibility	O
,	O
indicating	O
that	O
bard1	O
may	O
be	O
involved	O
in	O
mediating	O
tumour	B-Disease
suppression	O
by	O
brca1	O
.	O
	
.	O
	
45	O
-	O
kilobases	O
(	O
kb	O
)	O
exon	O
11	O
of	O
the	O
hereditary	B-Disease
breast	I-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
gene	O
brca1	O
.	O
	
autosomal	O
dominant	O
primary	O
hyperparathyroidism	B-Disease
and	I-Disease
jaw	I-Disease
tumor	I-Disease
syndrome	I-Disease
associated	O
with	O
renal	B-Disease
hamartomas	I-Disease
and	O
cystic	B-Disease
kidney	I-Disease
disease	I-Disease
:	O
linkage	O
to	O
1q21	O
-	O
q32	O
and	O
loss	O
of	O
the	O
wild	O
type	O
allele	O
in	O
renal	B-Disease
hamartomas	I-Disease
.	O
	
hereditary	B-Disease
hyperparathyroidism	I-Disease
-	I-Disease
jaw	I-Disease
tumor	I-Disease
syndrome	I-Disease
(	O
hpt	B-Disease
-	I-Disease
jt	I-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disease	I-Disease
(	O
omim	O
145001	O
)	O
that	O
has	O
recently	O
been	O
mapped	O
to	O
chromosomal	O
region	O
1q21	O
-	O
q32	O
(	O
hrpt2	O
)	O
.	O
	
here	O
we	O
report	O
two	O
families	O
with	O
hpt	B-Disease
-	I-Disease
jt	I-Disease
syndrome	I-Disease
in	O
which	O
adult	B-Disease
renal	I-Disease
hamartomas	I-Disease
or	O
cystic	B-Disease
kidney	I-Disease
disease	I-Disease
were	O
prominent	O
associated	O
features	O
,	O
possibly	O
representing	O
a	O
new	O
phenotypic	O
variant	O
of	O
the	O
hpt	B-Disease
-	I-Disease
jt	I-Disease
syndrome	I-Disease
.	O
	
in	O
the	O
first	O
family	O
,	O
renal	B-Disease
lesions	I-Disease
were	O
present	O
in	O
five	O
out	O
of	O
six	O
affected	O
individuals	O
,	O
whereas	O
hpt	B-Disease
and	O
jt	B-Disease
were	O
seen	O
in	O
four	O
and	O
two	O
cases	O
,	O
respectively	O
.	O
	
in	O
the	O
second	O
family	O
,	O
jt	B-Disease
was	O
found	O
in	O
three	O
of	O
the	O
five	O
affected	O
individuals	O
and	O
two	O
affected	O
members	O
also	O
exhibited	O
polycystic	B-Disease
kidney	I-Disease
disease	I-Disease
.	O
	
a	O
sex	O
-	O
dependent	O
penetrance	O
of	O
primary	B-Disease
hpt	I-Disease
,	O
resulting	O
in	O
predominantly	O
male	O
-	O
affected	O
cases	O
was	O
evident	O
in	O
the	O
two	O
families	O
.	O
	
twenty	O
microsatellite	O
markers	O
in	O
the	O
hrpt2	O
region	O
were	O
typed	O
,	O
in	O
addition	O
to	O
markers	O
in	O
the	O
multiple	B-Disease
endocrine	I-Disease
neoplasia	I-Disease
(	I-Disease
men	I-Disease
)	I-Disease
types	I-Disease
1	I-Disease
and	I-Disease
2	I-Disease
regions	O
at	O
11q13	O
and	O
10q11	O
.	O
	
the	O
disease	O
in	O
these	O
two	O
kindreds	O
was	O
linked	O
to	O
five	O
markers	O
in	O
the	O
1q21	O
-	O
q32	O
region	O
(	O
logarithm	O
-	O
of	O
-	O
odds	O
scores	O
3	O
.	O
	
2	O
-	O
4	O
2	O
-	O
4	O
.	O
	
2	O
)	O
,	O
whereas	O
linkage	O
to	O
the	O
men1	B-Disease
and	O
men2	B-Disease
regions	O
was	O
excluded	O
.	O
	
loss	O
of	O
heterozygosity	O
was	O
studied	O
in	O
seven	O
renal	B-Disease
hamartomas	I-Disease
from	O
two	O
affected	O
individuals	O
in	O
the	O
first	O
family	O
,	O
as	O
well	O
as	O
in	O
a	O
jaw	B-Disease
tumor	I-Disease
and	O
a	O
parathyroid	B-Disease
tumor	I-Disease
from	O
the	O
second	O
family	O
.	O
	
all	O
renal	B-Disease
hamartomas	I-Disease
showed	O
loss	O
of	O
heterozygosity	O
at	O
the	O
1q21	O
-	O
q32	O
region	O
.	O
	
the	O
losses	O
invariably	O
involved	O
the	O
wild	O
type	O
allele	O
derived	O
from	O
the	O
unaffected	O
parent	O
,	O
suggesting	O
the	O
inactivation	O
of	O
a	O
tumor	B-Disease
suppressor	O
gene	O
in	O
this	O
region	O
in	O
a	O
study	O
of	O
g6pd	B-Disease
deficient	I-Disease
patients	O
who	O
presented	O
with	O
clinical	O
favism	B-Disease
in	O
spain	O
,	O
we	O
have	O
found	O
a	O
new	O
polymorphic	O
variant	O
that	O
we	O
have	O
called	O
g6pd	O
malaga	O
,	O
whose	O
only	O
abnormality	O
is	O
a	O
542	O
a	O
-	O
-	O
>	O
t	O
(	O
181	O
asp	O
-	O
-	O
>	O
val	O
)	O
mutation	O
.	O
	
g6pd	O
malaga	O
is	O
associated	O
with	O
enzyme	B-Disease
deficiency	I-Disease
(	O
class	O
iii	O
)	O
,	O
and	O
the	O
enzymic	O
properties	O
of	O
g6pd	O
malaga	O
and	O
g6pd	O
santamaria	O
are	O
quite	O
similar	O
,	O
indicating	O
that	O
in	O
this	O
case	O
the	O
effects	O
of	O
the	O
two	O
mutations	O
are	O
additive	O
rather	O
than	O
synergistic	O
.	O
	
brca1	O
mutations	O
cause	O
increased	O
risk	O
for	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
,	O
frequently	O
of	O
early	O
onset	O
.	O
	
many	O
different	O
mutations	O
occur	O
in	O
brca1	O
,	O
including	O
several	O
examples	O
of	O
recurrent	O
mutations	O
,	O
each	O
of	O
which	O
accounts	O
for	O
a	O
significant	O
number	O
of	O
families	O
with	O
heritable	O
cancer	B-Disease
predisposition	O
.	O
	
these	O
common	O
mutations	O
have	O
an	O
etiological	O
role	O
in	O
many	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
cases	O
and	O
provide	O
the	O
opportunity	O
to	O
examine	O
genotype	O
-	O
phenotype	O
correlations	O
and	O
genotype	O
-	O
environment	O
interactions	O
in	O
individuals	O
with	O
the	O
identical	O
brca1	O
lesion	O
.	O
	
we	O
report	O
a	O
novel	O
missense	O
change	O
in	O
brca1	O
,	O
2640	O
c	O
-	O
-	O
>	O
t	O
(	O
r841w	O
)	O
,	O
found	O
in	O
3	O
cases	O
from	O
a	O
subject	O
group	O
of	O
305	O
breast	B-Disease
and	I-Disease
79	I-Disease
ovarian	I-Disease
cancer	I-Disease
cases	O
from	O
orange	O
county	O
,	O
ca	O
.	O
	
in	O
all	O
three	O
cases	O
,	O
there	O
is	O
a	O
strong	O
family	O
history	O
of	O
breast	B-Disease
,	I-Disease
ovarian	I-Disease
,	I-Disease
or	I-Disease
other	I-Disease
cancers	I-Disease
possibly	O
related	O
to	O
a	O
brca1	O
defect	O
and	O
family	O
members	O
showed	O
a	O
high	O
concordance	O
of	O
cancer	B-Disease
incidence	O
with	O
the	O
presence	O
of	O
r841w	O
.	O
	
the	O
age	O
of	O
cancer	B-Disease
onset	O
was	O
not	O
always	O
distinct	O
from	O
typical	O
sporadic	O
cases	O
.	O
	
testing	O
of	O
a	O
sample	O
of	O
413	O
unrelated	O
individuals	O
to	O
examine	O
the	O
hypothesis	O
that	O
r841w	O
might	O
be	O
a	O
rare	O
polymorphism	O
detected	O
one	O
additional	O
instance	O
in	O
a	O
woman	O
with	O
breast	B-Disease
cancer	I-Disease
diagnosed	O
at	O
age	O
77	O
years	O
,	O
and	O
cancer	B-Disease
in	O
one	O
parent	O
.	O
	
r841w	O
is	O
likely	O
to	O
be	O
an	O
etiologically	O
significant	O
lesion	O
with	O
involvement	O
in	O
close	O
to	O
1	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
of	O
0	O
-	O
1	O
.	O
	
7	O
%	O
)	O
of	O
all	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
in	O
this	O
population	O
.	O
	
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
:	O
founder	O
effect	O
among	O
north	O
african	O
jews	O
.	O
	
the	O
atm	O
gene	O
is	O
responsible	O
for	O
the	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
a	B-Disease
-	I-Disease
t	I-Disease
)	O
,	O
characterized	O
by	O
cerebellar	B-Disease
degeneration	I-Disease
,	O
immunodeficiency	B-Disease
and	O
cancer	B-Disease
predisposition	I-Disease
.	O
	
a	B-Disease
-	I-Disease
t	I-Disease
carriers	O
were	O
reported	O
to	O
be	O
moderately	O
cancer	B-Disease
-	I-Disease
prone	I-Disease
.	O
	
a	O
wide	O
variety	O
of	O
a	B-Disease
-	I-Disease
t	I-Disease
mutations	O
,	O
most	O
of	O
which	O
are	O
unique	O
to	O
single	O
families	O
,	O
were	O
identified	O
in	O
various	O
ethnic	O
groups	O
,	O
precluding	O
carrier	O
screening	O
with	O
mutation	O
-	O
specific	O
assays	O
.	O
	
however	O
,	O
a	O
single	O
mutation	O
was	O
observed	O
in	O
32	O
/	O
33	O
defective	O
atm	O
alleles	O
in	O
jewish	O
a	B-Disease
-	I-Disease
t	I-Disease
families	O
of	O
north	O
african	O
origin	O
,	O
coming	O
from	O
various	O
regions	O
of	O
morocco	O
and	O
tunisia	O
.	O
	
this	O
founder	O
effect	O
provides	O
a	O
unique	O
opportunity	O
for	O
population	O
-	O
based	O
screening	O
for	O
a	B-Disease
-	I-Disease
t	I-Disease
carriers	O
in	O
a	O
large	O
jewish	O
community	O
.	O
	
.	O
	
mutation	O
analysis	O
of	O
brca1	O
and	O
brca2	O
in	O
a	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
population	O
.	O
	
a	O
population	O
-	O
based	O
series	O
of	O
54	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
cases	O
from	O
southern	O
california	O
were	O
analyzed	O
for	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
inherited	B-Disease
breast	I-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
genes	O
,	O
brca1	O
and	O
brca2	O
.	O
	
nine	O
(	O
17	O
%	O
)	O
of	O
the	O
patients	O
had	O
a	O
family	O
history	O
of	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
in	O
at	O
least	O
one	O
first	O
-	O
degree	O
relative	O
.	O
	
a	O
further	O
seven	O
(	O
13	O
%	O
)	O
of	O
the	O
patients	O
reported	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
in	O
at	O
least	O
one	O
second	O
-	O
degree	O
relative	O
and	O
in	O
no	O
first	O
-	O
degree	O
relatives	O
.	O
	
two	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
patients	O
(	O
4	O
%	O
of	O
the	O
total	O
)	O
were	O
found	O
to	O
carry	O
novel	O
truncating	O
mutations	O
in	O
the	O
brca2	O
gene	O
.	O
	
only	O
one	O
of	O
the	O
two	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
patients	O
carrying	O
a	O
brca2	O
mutation	O
had	O
a	O
family	O
history	O
of	O
cancer	B-Disease
,	O
with	O
one	O
case	O
of	O
ovarian	B-Disease
cancer	I-Disease
in	O
a	O
first	O
-	O
degree	O
relative	O
.	O
	
the	O
remaining	O
eight	O
cases	O
(	O
89	O
%	O
)	O
of	O
male	B-Disease
breast	I-Disease
cancer	I-Disease
with	O
a	O
family	O
history	O
of	O
breast	B-Disease
/	I-Disease
ovarian	I-Disease
cancer	I-Disease
in	O
first	O
-	O
degree	O
relatives	O
remain	O
unaccounted	O
for	O
by	O
mutations	O
in	O
either	O
the	O
brca1	O
gene	O
or	O
the	O
brca2	O
gene	O
.	O
	
.	O
	
molecular	O
basis	O
for	O
duarte	B-Disease
and	I-Disease
los	I-Disease
angeles	I-Disease
variant	I-Disease
galactosemia	I-Disease
.	O
	
human	O
orythrocytes	O
that	O
are	O
homozygous	O
for	O
the	O
duarte	B-Disease
enzyme	I-Disease
variant	I-Disease
of	I-Disease
galactosemia	I-Disease
(	O
d	O
/	O
d	O
)	O
have	O
a	O
characteristic	O
isoform	O
on	O
isoelectric	O
focusing	O
and	O
50	O
%	O
reduction	O
in	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
(	O
galt	O
)	O
enzyme	O
activity	O
.	O
	
we	O
conclude	O
that	O
the	O
codon	O
change	O
n314d	O
in	O
cis	O
with	O
the	O
base	O
-	O
pair	O
transition	O
1721c	O
-	O
-	O
>	O
t	O
produces	O
the	O
la	B-Disease
variant	I-Disease
of	I-Disease
galactosemia	I-Disease
and	O
that	O
this	O
nucleotide	O
change	O
increases	O
galt	O
activity	O
by	O
increasing	O
galt	O
protein	O
abundance	O
without	O
increasing	O
transcription	O
or	O
decreasing	O
thermal	O
lability	O
.	O
	
the	O
tsg101	O
tumor	B-Disease
susceptibility	O
gene	O
is	O
located	O
in	O
chromosome	O
11	O
band	O
p15	O
and	O
is	O
mutated	O
in	O
human	O
breast	B-Disease
cancer	I-Disease
.	O
	
recent	O
work	O
has	O
identified	O
a	O
mouse	O
gene	O
(	O
tsg101	O
)	O
whose	O
inactivation	O
in	O
fibroblasts	O
results	O
in	O
cellular	O
transformation	O
and	O
the	O
ability	O
to	O
produce	O
metastatic	B-Disease
tumors	I-Disease
in	O
nude	O
mice	O
.	O
	
2	O
,	O
a	O
region	O
proposed	O
to	O
contain	O
tumor	B-Disease
suppressor	O
gene	O
(	O
s	O
)	O
,	O
is	O
mutated	O
at	O
high	O
frequency	O
in	O
human	O
breast	B-Disease
cancer	I-Disease
.	O
	
in	O
7	O
of	O
15	O
uncultured	O
primary	O
human	O
breast	B-Disease
carcinomas	I-Disease
,	O
intragenic	O
deletions	O
were	O
shown	O
in	O
tsg101	O
genomic	O
dna	O
and	O
transcripts	O
by	O
gel	O
and	O
sequence	O
analysis	O
,	O
and	O
mutations	O
affecting	O
two	O
tsg101	O
alleles	O
were	O
identified	O
in	O
four	O
of	O
these	O
cancers	B-Disease
.	O
	
no	O
tsg101	O
defects	O
were	O
found	O
in	O
matched	O
normal	O
breast	O
tissue	O
from	O
the	O
breast	B-Disease
cancer	I-Disease
patients	O
.	O
	
these	O
findings	O
strongly	O
implicate	O
tsg101	O
mutations	O
in	O
human	O
breast	B-Disease
cancer	I-Disease
myotonic	B-Disease
dystrophy	I-Disease
(	O
dm	B-Disease
)	O
is	O
associated	O
with	O
the	O
expansion	O
of	O
a	O
(	O
ctg	O
)	O
n	O
trinucleotide	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
(	O
utr	O
)	O
of	O
the	O
dm	B-Disease
protein	O
kinase	O
gene	O
(	O
dmpk	O
)	O
.	O
	
moreover	O
,	O
mitotic	O
instability	O
analysis	O
of	O
different	O
human	O
dm	B-Disease
tissues	O
shows	O
length	O
mosaicism	O
between	O
different	O
cell	O
lineages	O
.	O
	
missense	O
mutations	O
in	O
the	O
fas	O
gene	O
resulting	O
in	O
autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
:	O
a	O
molecular	O
and	O
immunological	O
analysis	O
.	O
	
the	O
fas	O
/	O
apo	O
-	O
1	O
receptor	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
apoptosis	O
,	O
as	O
demonstrated	O
by	O
lymphoproliferation	O
in	O
mrl	O
-	O
lpr	O
/	O
lpr	O
mice	O
and	O
by	O
the	O
recently	O
described	O
autoimmune	B-Disease
lymphoproliferative	I-Disease
syndrome	I-Disease
(	O
alps	B-Disease
)	O
in	O
humans	O
,	O
both	O
of	O
which	O
are	O
due	O
to	O
mutations	O
in	O
the	O
fas	O
gene	O
.	O
	
we	O
describe	O
a	O
novel	O
family	O
with	O
alps	B-Disease
in	O
which	O
three	O
affected	O
siblings	O
carry	O
two	O
distinct	O
missense	O
mutations	O
on	O
both	O
the	O
fas	O
gene	O
alleles	O
and	O
show	O
lack	O
of	O
fas	O
-	O
induced	O
apoptosis	O
.	O
	
the	O
children	O
share	O
common	O
clinical	O
features	O
including	O
splenomegaly	B-Disease
and	O
lymphadenopathy	B-Disease
,	O
but	O
only	O
one	O
developed	O
severe	O
autoimmune	B-Disease
manifestations	I-Disease
.	O
	
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
gene	O
product	O
,	O
a	O
constitutively	O
expressed	O
nuclear	O
protein	O
that	O
is	O
not	O
up	O
-	O
regulated	O
following	O
genome	O
damage	O
.	O
	
the	O
product	O
of	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
gene	O
(	O
atm	O
)	O
was	O
identified	O
by	O
using	O
an	O
antiserum	O
developed	O
to	O
a	O
peptide	O
corresponding	O
to	O
the	O
deduced	O
amino	O
acid	O
sequence	O
.	O
	
truncated	O
atm	O
protein	O
was	O
not	O
detected	O
in	O
lymphoblasts	O
from	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
patients	O
homozygous	O
for	O
mutations	O
leading	O
to	O
premature	O
protein	O
termination	O
.	O
	
mutations	O
in	O
the	O
col3a1	O
gene	O
have	O
been	O
implicated	O
as	O
a	O
cause	O
of	O
type	B-Disease
iv	I-Disease
ehlers	I-Disease
-	I-Disease
danlos	I-Disease
syndrome	I-Disease
,	O
a	O
disease	O
leading	O
to	O
aortic	B-Disease
rupture	I-Disease
in	O
early	O
adult	O
life	O
.	O
	
the	O
major	O
cause	O
of	O
death	O
of	O
mutant	O
mice	O
was	O
rupture	O
of	O
the	O
major	O
blood	O
vessels	O
,	O
similar	O
to	O
patients	O
with	O
type	B-Disease
iv	I-Disease
ehlers	I-Disease
-	I-Disease
danlos	I-Disease
syndrome	I-Disease
.	O
	
nonsense	O
mutation	O
in	O
exon	O
3	O
of	O
the	O
proteolipid	O
protein	O
gene	O
(	O
plp	O
)	O
in	O
a	O
family	O
with	O
an	O
unusual	O
form	O
of	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
.	O
	
we	O
report	O
a	O
g	O
-	O
-	O
>	O
a	O
transition	O
at	O
nucleotide	O
431	O
of	O
the	O
proteolipid	O
protein	O
gene	O
(	O
plp	O
)	O
results	O
in	O
a	O
nonsense	O
codon	O
in	O
a	O
family	O
with	O
an	O
unusual	O
form	O
of	O
pelizaeus	B-Disease
-	I-Disease
merzbacher	I-Disease
disease	I-Disease
(	O
pmd	B-Disease
)	O
.	O
	
the	O
clinical	O
picture	O
resembles	O
somewhat	O
that	O
of	O
x	B-Disease
-	I-Disease
linked	I-Disease
spastic	I-Disease
paraplegia	I-Disease
(	O
spg	B-Disease
)	O
.	O
	
it	O
differs	O
from	O
this	O
and	O
both	O
the	O
classical	O
and	O
connatal	O
forms	O
of	O
pmd	B-Disease
in	O
that	O
it	O
is	O
relatively	O
mild	O
in	O
form	O
,	O
onset	O
is	O
delayed	O
beyond	O
age	O
2	O
years	O
,	O
nystagmus	B-Disease
is	O
absent	O
,	O
tremors	B-Disease
are	O
prominent	O
,	O
mental	B-Disease
retardation	I-Disease
is	O
not	O
severe	O
,	O
some	O
patients	O
show	O
dementia	B-Disease
or	O
personality	B-Disease
disorders	I-Disease
,	O
the	O
disease	O
is	O
progressive	O
rather	O
than	O
static	O
in	O
some	O
,	O
and	O
several	O
females	O
show	O
signs	O
of	O
disease	O
.	O
	
the	O
nonsense	O
mutation	O
,	O
which	O
is	O
in	O
exon	O
3b	O
,	O
should	O
block	O
the	O
synthesis	O
of	O
normal	O
plp	O
but	O
spare	O
dm20	O
,	O
the	O
isoform	O
whose	O
persistence	O
has	O
been	O
associated	O
with	O
mild	O
forms	O
of	O
plp	B-Disease
-	I-Disease
associated	I-Disease
disease	I-Disease
in	O
both	O
humans	O
and	O
mice	O
.	O
	
.	O
	
common	O
brca1	O
variants	O
and	O
susceptibility	O
to	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
in	O
the	O
general	O
population	O
.	O
	
most	O
multiple	O
case	O
families	O
of	O
young	O
onset	O
breast	B-Disease
cancer	I-Disease
and	O
ovarian	B-Disease
cancer	I-Disease
are	O
thought	O
to	O
be	O
due	O
to	O
highly	O
penetrant	O
mutations	O
in	O
the	O
predisposing	O
genes	O
brca1	O
and	O
brca2	O
.	O
	
however	O
,	O
these	O
mutations	O
are	O
uncommon	O
in	O
the	O
population	O
and	O
they	O
probably	O
account	O
for	O
only	O
a	O
few	O
percent	O
of	O
all	O
breast	B-Disease
cancer	I-Disease
incidence	O
.	O
	
a	O
much	O
larger	O
fraction	O
of	O
breast	B-Disease
cancer	I-Disease
might	O
,	O
in	O
principle	O
,	O
be	O
due	O
to	O
common	O
variants	O
which	O
confer	O
more	O
modest	O
individual	O
risks	O
.	O
	
we	O
have	O
examined	O
the	O
frequency	O
of	O
four	O
of	O
these	O
polymorphisms	O
gln356arg	O
,	O
pro871leu	O
,	O
glu1038gly	O
and	O
ser1613gly	O
in	O
large	O
series	O
of	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
cases	O
and	O
matched	O
controls	O
.	O
	
thus	O
the	O
most	O
common	O
polymorphisms	O
of	O
the	O
brca1	O
gene	O
do	O
not	O
make	O
a	O
significant	O
contribution	O
to	O
breast	B-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
risk	O
.	O
	
however	O
,	O
our	O
data	O
suggest	O
that	O
the	O
arg356	O
allele	O
may	O
have	O
a	O
different	O
genotype	O
distribution	O
in	O
breast	B-Disease
cancer	I-Disease
patients	O
from	O
that	O
in	O
controls	O
(	O
arg356	O
homozygotes	O
are	O
more	O
frequent	O
in	O
the	O
control	O
groups	O
,	O
p	O
=	O
0	O
.	O
	
1	O
)	O
,	O
indicating	O
that	O
it	O
may	O
be	O
protective	O
against	O
breast	B-Disease
cancer	I-Disease
.	O
	
kniest	B-Disease
dysplasia	I-Disease
:	O
dr	O
.	O
	
w	O
.	O
	
kniest	B-Disease
dysplasia	I-Disease
is	O
a	O
severe	O
chondrodysplasia	B-Disease
caused	O
by	O
the	O
defective	B-Disease
formation	I-Disease
of	I-Disease
type	I-Disease
ii	I-Disease
collagen	I-Disease
.	O
	
we	O
report	O
about	O
dr	O
.	O
	
kniest	O
,	O
who	O
first	O
described	O
the	O
condition	O
in	O
1952	O
,	O
and	O
his	O
patient	O
,	O
who	O
,	O
at	O
the	O
age	O
of	O
50	O
years	O
is	O
severely	B-Disease
handicapped	I-Disease
with	O
short	B-Disease
stature	I-Disease
,	O
restricted	B-Disease
joint	I-Disease
mobility	I-Disease
,	O
and	O
blindness	B-Disease
but	O
is	O
mentally	O
alert	O
and	O
leads	O
an	O
active	O
life	O
.	O
	
this	O
is	O
in	O
accordance	O
with	O
molecular	O
findings	O
in	O
other	O
patients	O
with	O
kniest	B-Disease
dysplasia	I-Disease
and	O
confirms	O
,	O
in	O
the	O
original	O
patient	O
,	O
that	O
the	O
disorder	O
is	O
caused	O
by	O
small	O
inframe	O
deletions	O
often	O
due	O
to	O
exon	O
skipping	O
as	O
a	O
result	O
of	O
col2a1	O
splice	O
site	O
mutations	O
.	O
	
.	O
	
cloning	O
of	O
the	O
homogentisate	O
1	O
,	O
2	O
-	O
dioxygenase	O
gene	O
,	O
the	O
key	O
enzyme	O
of	O
alkaptonuria	B-Disease
in	O
mouse	O
.	O
	
this	O
corresponds	O
well	O
to	O
the	O
previous	O
assignment	O
of	O
the	O
locus	O
for	O
the	O
human	O
alkaptonuria	B-Disease
gene	O
(	O
aku	O
)	O
to	O
the	O
same	O
chromosomal	O
region	O
by	O
multipoint	O
linkage	O
analysis	O
.	O
	
we	O
therefore	O
conclude	O
that	O
the	O
hgo	O
cdna	O
encodes	O
the	O
gene	O
responsible	O
for	O
alkaptonuria	B-Disease
.	O
	
pten	O
,	O
a	O
putative	O
protein	O
tyrosine	O
phosphatase	O
gene	O
mutated	O
in	O
human	O
brain	B-Disease
,	I-Disease
breast	I-Disease
,	I-Disease
and	I-Disease
prostate	I-Disease
cancer	I-Disease
.	O
	
mapping	O
of	O
homozygous	O
deletions	O
on	O
human	O
chromosome	O
10q23	O
has	O
led	O
to	O
the	O
isolation	O
of	O
a	O
candidate	O
tumor	B-Disease
suppressor	O
gene	O
,	O
pten	O
,	O
that	O
appears	O
to	O
be	O
mutated	O
at	O
considerable	O
frequency	O
in	O
human	O
cancers	B-Disease
.	O
	
in	O
preliminary	O
screens	O
,	O
mutations	O
of	O
pten	O
were	O
detected	O
in	O
31	O
%	O
(	O
13	O
/	O
42	O
)	O
of	O
glioblastoma	B-Disease
cell	O
lines	O
and	O
xenografts	O
,	O
100	O
%	O
(	O
4	O
/	O
4	O
)	O
of	O
prostate	B-Disease
cancer	I-Disease
cell	O
lines	O
,	O
6	O
%	O
(	O
4	O
/	O
65	O
)	O
of	O
breast	B-Disease
cancer	I-Disease
cell	O
lines	O
and	O
xenografts	O
,	O
and	O
17	O
%	O
(	O
3	O
/	O
18	O
)	O
of	O
primary	B-Disease
glioblastomas	I-Disease
.	O
	
these	O
homologies	O
suggest	O
that	O
pten	O
may	O
suppress	O
tumor	B-Disease
cell	O
growth	O
by	O
antagonizing	O
protein	O
tyrosine	O
kinases	O
and	O
may	O
regulate	O
tumor	B-Disease
cell	O
invasion	O
and	O
metastasis	B-Disease
through	O
interactions	O
at	O
focal	O
adhesions	O
.	O
	
.	O
	
heterogeneity	O
in	O
schwartz	B-Disease
-	I-Disease
jampel	I-Disease
chondrodystrophic	I-Disease
myotonia	I-Disease
.	O
	
the	O
schwartz	B-Disease
-	I-Disease
jampel	I-Disease
syndrome	I-Disease
(	O
sjs	B-Disease
;	O
chondrodystrophic	B-Disease
myotonia	I-Disease
;	O
mck	O
255	O
,	O
800	O
)	O
is	O
a	O
recessively	B-Disease
inherited	I-Disease
condition	I-Disease
defined	O
by	O
myotonia	B-Disease
,	O
short	B-Disease
stature	I-Disease
,	O
and	O
bone	B-Disease
dysplasia	I-Disease
.	O
	
genetic	O
linkage	O
between	O
sjs	B-Disease
and	O
chromosomal	O
region	O
1q36	O
-	O
34	O
has	O
been	O
observed	O
in	O
several	O
families	O
,	O
but	O
the	O
gene	O
has	O
not	O
yet	O
been	O
identified	O
.	O
	
in	O
addition	O
,	O
we	O
tested	O
genetic	O
linkage	O
to	O
the	O
sjs	B-Disease
locus	O
on	O
chromosome	O
1	O
in	O
one	O
family	O
with	O
two	O
affected	O
sibs	O
.	O
	
we	O
found	O
that	O
a	O
group	O
of	O
patients	O
have	O
mild	O
skeletal	O
changes	O
which	O
may	O
be	O
secondary	O
consequences	O
of	O
myotonia	B-Disease
,	O
while	O
another	O
group	O
of	O
patients	O
appear	O
to	O
have	O
primary	O
bone	B-Disease
dysplasia	I-Disease
with	O
myotonia	B-Disease
.	O
	
we	O
tentatively	O
isolate	O
three	O
different	O
types	O
of	O
sjs	B-Disease
type	I-Disease
1a	I-Disease
,	O
usually	O
recognized	O
in	O
childhood	O
,	O
with	O
moderate	O
bone	B-Disease
dysplasia	I-Disease
,	O
corresponding	O
to	O
the	O
original	O
descriptions	O
of	O
schwartz	O
,	O
jampel	O
and	O
aberfeld	O
;	O
type	O
1b	O
,	O
similar	O
to	O
type	O
1a	O
but	O
recognizable	O
at	O
birth	O
,	O
with	O
more	O
pronounced	O
bone	B-Disease
dysplasia	I-Disease
resembling	O
kniest	B-Disease
dysplasia	I-Disease
;	O
and	O
type	O
2	O
,	O
manifest	O
at	O
birth	O
,	O
with	O
increased	O
mortality	O
and	O
bone	B-Disease
dysplasia	I-Disease
resembling	O
pyle	B-Disease
disease	I-Disease
.	O
	
genetic	O
analysis	O
of	O
the	O
family	O
with	O
two	O
sibs	O
affected	O
by	O
sjs	B-Disease
type	I-Disease
2	I-Disease
showed	O
evidence	O
against	O
linkage	O
to	O
chromosome	O
1p36	O
-	O
34	O
.	O
	
conclusions	O
sjs	B-Disease
is	O
clinically	O
and	O
radiologically	O
heterogeneous	O
.	O
	
the	O
causes	O
of	O
heterogeneity	O
are	O
not	O
known	O
yet	O
but	O
are	O
likely	O
to	O
include	O
both	O
different	O
mutations	O
at	O
the	O
sjs	B-Disease
locus	O
on	O
chromosome	O
1	O
and	O
the	O
presence	O
of	O
a	O
second	O
sjs	B-Disease
locus	O
.	O
	
mutations	O
in	O
the	O
wt1	O
gene	O
were	O
anticipated	O
to	O
explain	O
the	O
genetic	O
basis	O
of	O
the	O
childhood	O
kidney	B-Disease
cancer	I-Disease
,	O
wilms	B-Disease
tumour	I-Disease
(	O
wt	B-Disease
)	O
.	O
	
while	O
only	O
5	O
%	O
of	O
sporadic	B-Disease
wilms	I-Disease
tumours	I-Disease
have	O
intragenic	O
wt1	O
mutations	O
,	O
>	O
90	O
%	O
of	O
patients	O
with	O
the	O
denys	B-Disease
-	I-Disease
drash	I-Disease
syndrome	I-Disease
(	O
renal	B-Disease
nephropathy	I-Disease
,	O
gonadal	B-Disease
anomaly	I-Disease
,	O
predisposition	B-Disease
to	I-Disease
wt	I-Disease
)	O
carry	O
constitutional	O
intragenic	O
wt1	O
mutations	O
.	O
	
wt1	O
mutations	O
have	O
also	O
been	O
reported	O
in	O
juvenile	B-Disease
granulosa	I-Disease
cell	I-Disease
tumour	I-Disease
,	O
non	B-Disease
-	I-Disease
asbestos	I-Disease
related	I-Disease
mesothelioma	I-Disease
,	O
desmoplastic	B-Disease
small	I-Disease
round	I-Disease
cell	I-Disease
tumour	I-Disease
and	O
,	O
most	O
recently	O
,	O
acute	B-Disease
myeloid	I-Disease
leukemia	I-Disease
.	O
	
.	O
	
a	O
mutation	O
in	O
autosomal	B-Disease
dominant	I-Disease
myotonia	I-Disease
congenita	I-Disease
affects	O
pore	O
properties	O
of	O
the	O
muscle	O
chloride	O
channel	O
.	O
	
autosomal	B-Disease
dominant	I-Disease
myotonia	I-Disease
congenita	I-Disease
is	O
an	O
inherited	B-Disease
disorder	I-Disease
of	I-Disease
skeletal	I-Disease
muscle	I-Disease
caused	O
by	O
mutations	O
in	O
a	O
voltage	O
-	O
gated	O
cl	O
-	O
channel	O
gene	O
(	O
clcn1	O
,	O
7q35	O
)	O
.	O
	
the	O
incidence	O
of	O
pax6	O
mutation	O
in	O
patients	O
with	O
simple	O
aniridia	B-Disease
:	O
an	O
evaluation	O
of	O
mutation	O
detection	O
in	O
12	O
cases	O
.	O
	
twelve	O
aniridia	B-Disease
patients	O
,	O
five	O
with	O
a	O
family	O
history	O
and	O
seven	O
presumed	O
to	O
be	O
sporadic	O
,	O
were	O
exhaustively	O
screened	O
in	O
order	O
to	O
test	O
what	O
proportion	O
of	O
people	O
with	O
aniridia	B-Disease
,	O
uncomplicated	O
by	O
associated	O
anomalies	O
,	O
carry	O
mutations	O
in	O
the	O
human	O
pax6	O
gene	O
.	O
	
insulin	O
gene	O
region	O
contributes	O
to	O
genetic	O
susceptibility	O
to	O
,	O
but	O
may	O
not	O
to	O
low	O
incidence	O
of	O
,	O
insulin	B-Disease
-	I-Disease
dependent	I-Disease
diabetes	I-Disease
mellitus	I-Disease
in	O
japanese	O
.	O
	
in	O
the	O
caucasian	O
population	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
the	O
insulin	O
gene	O
(	O
ins	O
)	O
region	O
contains	O
the	O
insulin	B-Disease
-	I-Disease
dependent	I-Disease
diabetes	I-Disease
mellitus	I-Disease
locus	O
(	O
iddm2	O
)	O
.	O
	
in	O
the	O
japanese	O
population	O
,	O
however	O
,	O
there	O
has	O
been	O
no	O
report	O
demonstrating	O
the	O
contribution	O
of	O
iddm2	O
to	O
the	O
pathogenesis	O
of	O
iddm	B-Disease
.	O
	
we	O
conducted	O
an	O
association	O
study	O
of	O
iddm	B-Disease
in	O
a	O
large	O
number	O
of	O
japanese	O
subjects	O
with	O
multiple	O
polymorphisms	O
in	O
ins	O
region	O
.	O
	
we	O
found	O
a	O
significant	O
association	O
of	O
the	O
ins	O
region	O
with	O
iddm	B-Disease
.	O
	
alleles	O
positively	O
associated	O
with	O
iddm	B-Disease
in	O
ins	O
region	O
were	O
the	O
same	O
as	O
those	O
positively	O
-	O
associated	O
with	O
iddm	B-Disease
in	O
caucasian	O
population	O
,	O
although	O
positively	O
-	O
associated	O
alleles	O
are	O
very	O
common	O
(	O
allele	O
frequencies	O
>	O
0	O
.	O
	
9	O
)	O
in	O
the	O
japanese	O
general	O
population	O
.	O
	
these	O
data	O
suggest	O
that	O
iddm2	O
is	O
involved	O
in	O
the	O
genetic	O
susceptibility	O
to	O
iddm	B-Disease
in	O
japanese	O
.	O
	
the	O
high	O
frequencies	O
of	O
disease	O
-	O
associated	O
alleles	O
in	O
the	O
general	O
population	O
suggest	O
that	O
iddm2	O
locus	O
is	O
not	O
responsible	O
for	O
the	O
low	O
incidence	O
of	O
iddm	B-Disease
in	O
japanese	O
.	O
	
deficiency	B-Disease
of	I-Disease
terminal	I-Disease
complement	I-Disease
components	I-Disease
is	O
generally	O
associated	O
with	O
recurrent	O
neisseria	B-Disease
infections	I-Disease
.	O
	
we	O
studied	O
a	O
previously	O
described	O
swiss	O
family	O
with	O
inherited	B-Disease
c9	I-Disease
deficiency	I-Disease
.	O
	
to	O
identify	O
the	O
genetic	O
basis	O
of	O
c9	B-Disease
deficiency	I-Disease
,	O
we	O
developed	O
an	O
approach	O
using	O
exon	O
-	O
specific	O
pcr	O
and	O
direct	O
dna	O
sequencing	O
.	O
	
as	O
a	O
cause	O
of	O
c9	B-Disease
deficiency	I-Disease
,	O
we	O
found	O
two	O
different	O
point	O
mutations	O
,	O
both	O
generating	O
tga	O
stop	O
codons	O
in	O
the	O
coding	O
sequence	O
.	O
	
in	O
family	O
studies	O
of	O
three	O
first	O
-	O
degree	O
relatives	O
with	O
heterozygous	O
c9	B-Disease
deficiency	I-Disease
,	O
we	O
demonstrated	O
that	O
the	O
two	O
mutations	O
are	O
segregating	O
independently	O
.	O
	
brca1	O
mutations	O
in	O
women	O
attending	O
clinics	O
that	O
evaluate	O
the	O
risk	O
of	O
breast	B-Disease
cancer	I-Disease
.	O
	
background	O
to	O
define	O
the	O
incidence	O
of	O
brca1	O
mutations	O
among	O
patients	O
seen	O
in	O
clinics	O
that	O
evaluate	O
the	O
risk	O
of	O
breast	B-Disease
cancer	I-Disease
,	O
we	O
analyzed	O
dna	O
samples	O
from	O
women	O
seen	O
in	O
this	O
setting	O
and	O
constructed	O
probability	O
tables	O
to	O
provide	O
estimates	O
of	O
the	O
likelihood	O
of	O
finding	O
a	O
brca1	O
mutation	O
in	O
individual	O
families	O
.	O
	
methods	O
clinical	O
information	O
,	O
family	O
histories	O
,	O
and	O
blood	O
for	O
dna	O
analysis	O
were	O
obtained	O
from	O
263	O
women	O
with	O
breast	B-Disease
cancer	I-Disease
.	O
	
results	O
brca1	O
mutations	O
were	O
identified	O
in	O
16	O
percent	O
of	O
women	O
with	O
a	O
family	O
history	O
of	O
breast	B-Disease
cancer	I-Disease
.	O
	
only	O
7	O
percent	O
of	O
women	O
from	O
families	O
with	O
a	O
history	O
of	O
breast	B-Disease
cancer	I-Disease
but	O
not	O
ovarian	B-Disease
cancer	I-Disease
had	O
brca1	O
mutations	O
.	O
	
the	O
rates	O
were	O
higher	O
among	O
women	O
from	O
families	O
with	O
a	O
history	O
of	O
both	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
	
among	O
family	O
members	O
,	O
an	O
average	O
age	O
of	O
less	O
than	O
55	O
years	O
at	O
the	O
diagnosis	O
of	O
breast	B-Disease
cancer	I-Disease
,	O
the	O
presence	O
of	O
ovarian	B-Disease
cancer	I-Disease
,	O
the	O
presence	O
of	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
in	O
the	O
same	O
woman	O
,	O
and	O
ashkenazi	O
jewish	O
ancestry	O
were	O
all	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
detecting	O
a	O
brca1	O
mutation	O
.	O
	
no	O
association	O
was	O
found	O
between	O
the	O
presence	O
of	O
bilateral	O
breast	B-Disease
cancer	I-Disease
or	O
the	O
number	O
of	O
breast	B-Disease
cancers	I-Disease
in	O
a	O
family	O
and	O
the	O
detection	O
of	O
a	O
brca1	O
mutation	O
,	O
or	O
between	O
the	O
position	O
of	O
the	O
mutation	O
in	O
the	O
brca1	O
gene	O
and	O
the	O
presence	O
of	O
ovarian	B-Disease
cancer	I-Disease
in	O
a	O
family	O
.	O
	
conclusions	O
among	O
women	O
with	O
breast	B-Disease
cancer	I-Disease
and	O
a	O
family	O
history	O
of	O
the	O
disease	O
,	O
the	O
percentage	O
with	O
brca1	O
coding	O
-	O
region	O
mutations	O
is	O
less	O
than	O
the	O
45	O
percent	O
predicted	O
by	O
genetic	O
-	O
linkage	O
analysis	O
.	O
	
mutations	O
in	O
the	O
arginine	O
-	O
rich	O
protein	O
gene	O
(	O
arp	O
)	O
in	O
pancreatic	B-Disease
cancer	I-Disease
.	O
	
at	O
the	O
cytogenetic	O
level	O
this	O
region	O
is	O
frequently	O
deleted	O
in	O
a	O
variety	O
of	O
different	O
solid	B-Disease
tumors	I-Disease
,	O
although	O
not	O
in	O
pancreatic	B-Disease
cancer	I-Disease
.	O
	
we	O
have	O
reported	O
the	O
presence	O
of	O
a	O
specific	O
mutation	O
(	O
atg50	O
-	O
-	O
>	O
agg	O
)	O
or	O
deletion	O
of	O
codon	O
50	O
of	O
the	O
arp	O
gene	O
in	O
different	O
tumor	B-Disease
types	I-Disease
(	O
shridhar	O
et	O
al	O
.	O
	
,	O
1996	O
,	O
1996a	O
)	O
.	O
	
in	O
the	O
present	O
study	O
,	O
we	O
have	O
observed	O
mutations	O
involving	O
codon	O
50	O
in	O
11	O
of	O
37	O
pancreatic	B-Disease
tumors	I-Disease
.	O
	
the	O
frequency	O
of	O
codon	O
50	O
mutation	O
is	O
roughly	O
the	O
same	O
in	O
pancreatic	B-Disease
tumors	I-Disease
as	O
in	O
the	O
other	O
types	O
of	O
tumors	B-Disease
previously	O
examined	O
.	O
	
in	O
addition	O
,	O
we	O
have	O
detected	O
mutations	O
at	O
codon	O
51	O
in	O
multiple	O
pcr	O
subclones	O
in	O
two	O
other	O
pancreatic	B-Disease
tumors	I-Disease
.	O
	
mutations	O
in	O
the	O
arp	O
gene	O
are	O
thus	O
commonly	O
observed	O
in	O
pancreatic	B-Disease
cancer	I-Disease
,	O
as	O
well	O
as	O
many	O
other	O
cancers	B-Disease
.	O
	
difficulties	O
in	O
the	O
ascertainment	O
of	O
c9	B-Disease
deficiency	I-Disease
:	O
lessons	O
to	O
be	O
drawn	O
from	O
a	O
compound	O
heterozygote	O
c9	B-Disease
-	I-Disease
deficient	I-Disease
subject	O
.	O
	
the	O
patient	O
was	O
shown	O
to	O
be	O
heterozygous	O
for	O
dna	O
markers	O
in	O
the	O
c6	O
,	O
c7	O
and	O
c9	O
region	O
of	O
chromosome	O
5	O
and	O
therefore	O
appears	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
uncharacterized	O
c9	B-Disease
deficiency	I-Disease
genes	O
.	O
	
we	O
hypothesize	O
that	O
the	O
patient	O
is	O
heterozygous	O
for	O
a	O
complete	B-Disease
deficiency	I-Disease
of	I-Disease
c9	I-Disease
and	O
for	O
a	O
gene	O
directing	O
hyposynthesis	O
of	O
a	O
defective	O
c9	O
.	O
	
we	O
also	O
suggest	O
that	O
c9	B-Disease
deficiency	I-Disease
may	O
be	O
more	O
common	O
among	O
caucasians	O
than	O
has	O
been	O
reported	O
.	O
	
.	O
	
screening	O
for	O
esr	O
mutations	O
in	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
patients	O
.	O
	
in	O
the	O
present	O
study	O
,	O
leukocyte	O
dna	O
from	O
143	O
patients	O
with	O
familial	O
clustering	O
of	O
breast	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
and	O
tumour	B-Disease
dna	O
from	O
96	O
breast	B-Disease
carcinomas	I-Disease
were	O
screened	O
for	O
base	O
mutations	O
in	O
the	O
estrogen	O
receptor	O
gene	O
(	O
esr	O
)	O
.	O
	
three	O
patients	O
with	O
a	O
family	O
history	O
of	O
cancer	B-Disease
were	O
carrying	O
a	O
gly160cys	O
germline	O
substitution	O
.	O
	
however	O
,	O
in	O
the	O
229	O
female	O
controls	O
in	O
whom	O
family	O
history	O
of	O
cancer	B-Disease
was	O
known	O
,	O
one	O
of	O
two	O
who	O
had	O
a	O
sister	O
with	O
breast	B-Disease
cancer	I-Disease
was	O
carrying	O
the	O
variant	O
allele	O
.	O
	
somatic	O
mutations	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
tumours	B-Disease
studied	O
,	O
and	O
the	O
present	O
data	O
do	O
not	O
provide	O
support	O
for	O
somatic	O
esr	O
base	O
mutations	O
as	O
an	O
important	O
mechanism	O
for	O
hormonal	O
therapy	O
resistance	O
in	O
estrogen	B-Disease
receptor	I-Disease
-	I-Disease
positive	I-Disease
breast	I-Disease
carcinomas	I-Disease
.	O
	
.	O
	
molecular	O
bases	O
of	O
c7	B-Disease
deficiency	I-Disease
:	O
three	O
different	O
defects	O
.	O
	
the	O
molecular	O
basis	O
of	O
c7	B-Disease
deficiency	I-Disease
has	O
been	O
investigated	O
in	O
two	O
irish	O
families	O
and	O
a	O
number	O
of	O
israeli	O
families	O
of	O
moroccan	O
sephardic	O
jewish	O
origin	O
.	O
	
the	O
israeli	O
c7	B-Disease
-	I-Disease
deficient	I-Disease
cases	O
all	O
share	O
a	O
c7	O
haplotype	O
and	O
are	O
homozygous	O
for	O
a	O
mis	O
-	O
sense	O
mutation	O
in	O
exon	O
9	O
.	O
	
molecular	O
heterogeneity	O
of	O
classical	B-Disease
and	I-Disease
duarte	I-Disease
galactosemia	I-Disease
:	O
mutation	O
analysis	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
.	O
	
classical	B-Disease
galactosemia	I-Disease
is	O
caused	O
by	O
one	O
common	O
missense	O
mutation	O
(	O
q188r	O
)	O
and	O
by	O
several	O
rare	O
mutations	O
in	O
the	O
galactose	O
-	O
1	O
-	O
phosphate	O
uridyltransferase	O
(	O
galt	O
)	O
gene	O
.	O
	
to	O
study	O
the	O
molecular	O
genetics	O
of	O
classical	B-Disease
and	I-Disease
duarte	I-Disease
galactosemia	I-Disease
,	O
we	O
analyzed	O
the	O
galt	O
mutations	O
in	O
30	O
families	O
with	O
classical	B-Disease
galactosemia	I-Disease
,	O
in	O
10	O
families	O
with	O
the	O
d	O
-	O
2	O
variant	O
and	O
in	O
3	O
individuals	O
carrying	O
the	O
d	O
-	O
1	O
allele	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
dgge	O
)	O
.	O
	
dgge	O
detected	O
59	O
of	O
the	O
60	O
classical	O
galactosemia	B-Disease
alleles	O
.	O
	
eight	O
novel	O
candidate	O
galactosemia	B-Disease
mutations	O
were	O
found	O
.	O
	
we	O
conclude	O
that	O
the	O
mutations	O
causing	O
galactosemia	B-Disease
are	O
highly	O
heterogeneous	O
and	O
that	O
k285n	O
is	O
a	O
second	O
common	O
galactosemia	B-Disease
mutation	O
in	O
our	O
population	O
.	O
	
.	O
	
isolation	O
of	O
full	O
-	O
length	O
atm	O
cdna	O
and	O
correction	O
of	O
the	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
cellular	O
phenotype	O
.	O
	
a	O
gene	O
mutated	O
in	O
the	O
human	O
genetic	B-Disease
disorder	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
a	B-Disease
-	I-Disease
t	I-Disease
)	O
,	O
atm	O
,	O
was	O
recently	O
identified	O
by	O
positional	O
cloning	O
.	O
	
we	O
describe	O
herein	O
,	O
to	O
our	O
knowledge	O
,	O
for	O
the	O
first	O
time	O
,	O
the	O
cloning	O
of	O
a	O
full	O
-	O
length	O
cdna	O
for	O
atm	O
and	O
correction	O
of	O
multiple	O
aspects	O
of	O
the	O
radio	O
-	O
sensitive	O
phenotype	O
of	O
a	B-Disease
-	I-Disease
t	I-Disease
cells	O
by	O
transfection	O
with	O
this	O
cdna	O
.	O
	
overexpression	O
of	O
atm	O
cdna	O
in	O
a	B-Disease
-	I-Disease
t	I-Disease
cells	O
enhanced	O
the	O
survival	O
of	O
these	O
cells	O
in	O
response	O
to	O
radiation	O
exposure	O
,	O
decreased	O
radiation	O
-	O
induced	O
chromosome	O
aberrations	O
,	O
reduced	O
radio	O
-	O
resistant	O
dna	O
synthesis	O
,	O
and	O
partially	O
corrected	O
defective	O
cell	O
cycle	O
checkpoints	O
and	O
induction	O
of	O
stress	O
-	O
activated	O
protein	O
kinase	O
.	O
	
this	O
correction	O
of	O
the	O
defects	O
in	O
a	B-Disease
-	I-Disease
t	I-Disease
cells	O
provides	O
further	O
evidence	O
of	O
the	O
multiplicity	O
of	O
effector	O
functions	O
of	O
the	O
atm	O
protein	O
and	O
suggests	O
possible	O
approaches	O
to	O
gene	O
therapy	O
.	O
	
.	O
	
fusion	O
genes	O
resulting	O
from	O
alternative	O
chromosomal	O
translocations	O
are	O
overexpressed	O
by	O
gene	O
-	O
specific	O
mechanisms	O
in	O
alveolar	B-Disease
rhabdomyosarcoma	I-Disease
.	O
	
chromosomal	O
translocations	O
identified	O
in	O
hematopoietic	B-Disease
and	I-Disease
solid	I-Disease
tumors	I-Disease
result	O
in	O
deregulated	O
expression	O
of	O
protooncogenes	O
or	O
creation	O
of	O
chimeric	O
proteins	O
with	O
tumorigenic	O
potential	O
.	O
	
in	O
the	O
pediatric	O
solid	B-Disease
tumor	I-Disease
alveolar	B-Disease
rhabdomyosarcoma	I-Disease
,	O
a	O
consistent	O
t	O
(	O
2	O
;	O
13	O
)	O
(	O
q35	O
;	O
q14	O
)	O
or	O
variant	O
t	O
(	O
1	O
;	O
13	O
)	O
(	O
p36	O
;	O
q14	O
)	O
translocation	O
generates	O
pax3	O
-	O
fkhr	O
or	O
pax7	O
-	O
fkhr	O
fusion	O
proteins	O
,	O
respectively	O
.	O
	
thus	O
,	O
gene	O
-	O
specific	O
mechanisms	O
were	O
selected	O
to	O
overexpress	O
pax3	O
-	O
fkhr	O
and	O
pax7	O
-	O
fkhr	O
in	O
alveolar	B-Disease
rhabdomyosarcoma	I-Disease
,	O
presumably	O
due	O
to	O
differences	O
in	O
regulation	O
between	O
the	O
wild	O
-	O
type	O
loci	O
.	O
	
atm	O
and	O
p53	O
cooperate	O
in	O
apoptosis	O
and	O
suppression	O
of	O
tumorigenesis	O
,	O
but	O
not	O
in	O
resistance	O
to	O
acute	B-Disease
radiation	I-Disease
toxicity	I-Disease
.	O
	
mutations	O
in	O
atm	O
and	O
p53	O
cause	O
the	O
human	O
cancer	B-Disease
-	I-Disease
associated	I-Disease
diseases	I-Disease
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
and	O
li	B-Disease
-	I-Disease
fraumeni	I-Disease
syndrome	I-Disease
,	O
respectively	O
.	O
	
atm	O
-	O
nan	O
mice	O
,	O
as	O
well	O
as	O
those	O
nan	O
for	O
p53	O
,	O
develop	O
mainly	O
t	B-Disease
-	I-Disease
cell	I-Disease
lymphomas	I-Disease
,	O
supporting	O
the	O
view	O
that	O
these	O
genes	O
have	O
similar	O
roles	O
in	O
thymocyte	O
development	O
.	O
	
mice	O
doubly	O
nan	O
for	O
atm	O
and	O
p53	O
exhibited	O
a	O
dramatic	O
acceleration	O
of	O
tumour	B-Disease
formation	O
relative	O
to	O
singly	O
nan	O
mice	O
,	O
indicating	O
that	O
both	O
genes	O
collaborate	O
in	O
a	O
significant	O
manner	O
to	O
prevent	O
tumorigenesis	O
.	O
	
finally	O
-	O
and	O
in	O
contrast	O
to	O
prior	O
predictions	O
-	O
atm	O
and	O
p53	O
do	O
not	O
appear	O
to	O
interact	O
in	O
acute	B-Disease
radiation	I-Disease
toxicity	I-Disease
,	O
suggesting	O
a	O
separate	O
atm	O
effector	O
pathway	O
for	O
this	O
dna	O
damage	O
response	O
and	O
having	O
implications	O
for	O
the	O
prognosis	O
and	O
treatment	O
of	O
human	O
tumours	B-Disease
.	O
	
.	O
	
trinucleotide	O
repeat	O
expansion	O
at	O
the	O
myotonic	B-Disease
dystrophy	I-Disease
locus	O
reduces	O
expression	O
of	O
dmahp	O
.	O
	
myotonic	B-Disease
dystrophy	I-Disease
,	O
or	O
dystrophia	B-Disease
myotonica	I-Disease
(	O
dm	B-Disease
)	O
,	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
multisystem	I-Disease
disorder	I-Disease
caused	O
by	O
the	O
expansion	O
of	O
a	O
ctg	O
trinucleotide	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
dmpk	O
protein	O
kinase	O
gene	O
on	O
chromosome	O
19q13	O
.	O
	
although	O
the	O
dm	B-Disease
mutation	O
was	O
identified	O
more	O
than	O
five	O
years	O
ago	O
,	O
the	O
pathogenic	O
mechanisms	O
underlying	O
this	O
most	O
prevalent	O
form	O
of	O
hereditary	O
adult	O
neuromuscular	B-Disease
disease	I-Disease
remain	O
elusive	O
.	O
	
analysis	O
of	O
dmahp	O
expression	O
in	O
the	O
cells	O
of	O
dm	B-Disease
patients	O
with	O
loss	O
of	O
the	O
hypersensitive	O
site	O
revealed	O
a	O
two	O
-	O
to	O
fourfold	O
reduction	O
in	O
steady	O
-	O
state	O
dmahp	O
transcript	O
levels	O
relative	O
to	O
wild	O
-	O
type	O
controls	O
.	O
	
together	O
,	O
these	O
results	O
demonstrate	O
that	O
ctg	O
-	O
repeat	O
expansions	O
can	O
suppress	O
local	O
gene	O
expression	O
and	O
implicate	O
dmahp	O
in	O
dm	B-Disease
pathogenesis	O
.	O
	
constitutively	O
methylated	O
cpg	O
dinucleotides	O
as	O
mutation	O
hot	O
spots	O
in	O
the	O
retinoblastoma	B-Disease
gene	O
(	O
rb1	O
)	O
.	O
	
a	O
wide	O
spectrum	O
of	O
mutations	O
,	O
ranging	O
from	O
point	O
mutations	O
to	O
large	O
deletions	O
,	O
have	O
been	O
described	O
in	O
the	O
retinoblastoma	B-Disease
gene	O
(	O
rb1	O
)	O
.	O
	
the	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
tumor	I-Disease
suppressor	O
gene	O
product	O
interacts	O
with	O
sp1	O
to	O
repress	O
vascular	O
endothelial	O
growth	O
factor	O
promoter	O
activity	O
.	O
	
the	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
tumor	I-Disease
suppressor	O
gene	O
(	O
vhl	O
)	O
has	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
clear	B-Disease
-	I-Disease
cell	I-Disease
renal	I-Disease
cell	I-Disease
carcinoma	I-Disease
(	O
rcc	B-Disease
)	O
,	O
as	O
vhl	O
mutations	O
have	O
been	O
found	O
in	O
both	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
disease	I-Disease
-	I-Disease
associated	I-Disease
and	I-Disease
sporadic	I-Disease
rccs	I-Disease
.	O
	
recent	O
studies	O
suggest	O
that	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
vegf	O
)	O
mrna	O
is	O
upregulated	O
in	O
rcc	B-Disease
-	I-Disease
and	I-Disease
von	I-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
disease	I-Disease
-	I-Disease
associated	I-Disease
tumors	I-Disease
.	O
	
vegf	O
promoter	O
-	O
luciferase	O
constructs	O
were	O
transiently	O
cotransfected	O
with	O
a	O
wild	O
-	O
type	O
vhl	O
(	O
wt	O
-	O
vhl	O
)	O
vector	O
in	O
several	O
cell	O
lines	O
,	O
including	O
293	O
embryonic	O
kidney	O
and	O
rcc	B-Disease
cell	O
lines	O
.	O
	
furthermore	O
,	O
endogenous	O
vegf	O
mrna	O
levels	O
were	O
suppressed	O
in	O
permanent	O
rcc	B-Disease
cell	O
lines	O
expressing	O
wt	O
-	O
vhl	O
,	O
and	O
nuclear	O
run	O
-	O
on	O
studies	O
indicated	O
that	O
vhl	O
regulation	O
of	O
vegf	O
occurs	O
at	O
least	O
partly	O
at	O
the	O
transcriptional	O
level	O
.	O
	
these	O
observations	O
support	O
a	O
new	O
mechanism	O
for	O
vhl	O
-	O
mediated	O
transcriptional	O
repression	O
via	O
a	O
direct	O
inhibitory	O
action	O
on	O
sp1	O
and	O
suggest	O
that	O
loss	O
of	O
sp1	O
inhibition	O
may	O
be	O
important	O
in	O
the	O
pathogenesis	O
of	O
von	B-Disease
hippel	I-Disease
-	I-Disease
lindau	I-Disease
disease	I-Disease
and	O
rcc	B-Disease
.	O
	
.	O
	
adult	B-Disease
onset	I-Disease
globoid	I-Disease
cell	I-Disease
leukodystrophy	I-Disease
(	O
krabbe	B-Disease
disease	I-Disease
)	O
:	O
analysis	O
of	O
galactosylceramidase	O
cdna	O
from	O
four	O
japanese	O
patients	O
.	O
	
we	O
examined	O
galactosylceramidase	O
(	O
galc	O
)	O
cdna	O
in	O
four	O
japanese	O
patients	O
with	O
adult	B-Disease
onset	I-Disease
globoid	I-Disease
cell	I-Disease
leukodystrophy	I-Disease
(	O
krabbe	B-Disease
disease	I-Disease
;	O
ao	B-Disease
-	I-Disease
gld	I-Disease
)	O
by	O
polymerase	O
chain	O
reaction	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
pcr	O
-	O
sscp	O
)	O
analysis	O
,	O
subsequent	O
sequence	O
determination	O
,	O
and	O
restriction	O
enzyme	O
digestion	O
of	O
pcr	O
products	O
,	O
initial	O
symptoms	O
were	O
the	O
onset	O
of	O
slowly	O
progressive	O
spastic	B-Disease
paraplegia	I-Disease
from	O
the	O
middle	O
of	O
the	O
second	O
decade	O
,	O
and	O
all	O
patients	O
had	O
diminished	B-Disease
galc	I-Disease
activity	I-Disease
in	O
their	O
leukocytes	O
.	O
	
three	O
mutations	O
,	O
viz	O
.	O
	
,	O
g270d	O
,	O
l618s	O
,	O
and	O
exon	O
-	O
6	O
skipping	O
(	O
535	O
-	O
573del	O
)	O
,	O
produced	O
diminished	B-Disease
galc	I-Disease
activity	I-Disease
as	O
expected	O
.	O
	
ao	B-Disease
-	I-Disease
gld	I-Disease
mutations	O
,	O
including	O
those	O
found	O
here	O
,	O
are	O
located	O
in	O
the	O
n	O
-	O
terminus	O
(	O
i66m	O
,	O
g270d	O
,	O
535	O
-	O
573del	O
)	O
or	O
c	O
-	O
terminus	O
(	O
l618s	O
)	O
of	O
the	O
galc	O
enzyme	O
,	O
whereas	O
the	O
reported	O
mutations	O
in	O
the	O
infantile	O
form	O
(	O
if	B-Disease
-	I-Disease
gld	I-Disease
)	O
are	O
in	O
the	O
central	O
domain	O
.	O
	
this	O
difference	O
in	O
mutation	O
sites	O
may	O
affect	O
the	O
clinical	O
features	O
of	O
gld	B-Disease
.	O
	
